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THE ROLE OF SNAI2/SLUG IN DIABETES-IMPAIRED WOUND HEALING

By
Krystle K. Quan

B.S. Biochemistry, University of Washington, Seattle
Ph.D. Biomedical Sciences, University of New Mexico, Albuquerque

ABSTRACT
Impaired wound healing is a common complication of diabetes mellitus.
Advanced glycation end products (AGEs) are a consequence of diabetes and are formed
from non-enzymatic reactions between glucose and proteins. The accumulation of AGEs
is believed to disrupt wound repair and alter protein function. The epidermal growth
factor receptor (EGFR) and a downstream effector, Snai2/Slug, are key regulators of
reepithelialization, a vital component of wound healing. Reepithelialization requires
keratinocyte proliferation and migration. Therefore, we examined the impact of AGEs on
these EGF-stimulated responses. In this dissertation, I present evidence for a critical role
of Snai2 in diabetes-impaired wound reepithelialization, extending the knowledge of
Snai2 past normal wound repair. A well-studied AGE precursor, glyoxal, was used to
model a diabetic environment. Glyoxal decreased EGF-stimulated EGFR activation,
leading to impaired keratinocyte proliferation and migration in cell culture and in tissue
explants. EGF-stimulated and basal Snai2 protein levels decreased following glyoxal
treatment, and this decrease was prevented by the glycation inhibitor, aminoguanidine.
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Snai2 immunoprecipitated from glyoxal-exposed cells was modified by the AGE product
carboxymethyl lysine, identifying Snai2 as an intracellular target of glycation.
Furthermore, mice over-expressing Snai2 demonstrated enhanced epithelial outgrowth
compared to wild type mice when exposed to glyoxal ex vivo. These data represent a
significant breakthrough in the field of diabetes and wound healing as it is the first
evidence linking Snai2 down-regulation by pathophysiologic stimuli to impairments in
reepithelialization. In addition, few intracellular proteins have been identified as targets
of glycation, and this work highlights Snai2 as a novel nuclear protein target with
demonstrated relevance to diabetic healing.

With this knowledge, we may explore

methods to pharmacologically induce Snai2 protein to promote healing of diabetic
wounds.
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CHAPTER 1
Introduction
1.1 Diabetes: overview
Diabetes mellitus is a metabolic disorder in which people with high blood sugar
(hyperglycemia) are unable to regulate and reduce sugar levels (Galtier, 2010;
Hotamisligil, 2006). According to the American Diabetes Association and the Centers
for Disease Control and Prevention, diabetes was the seventh leading cause of death in
the United States in 2011, and it is believed that death caused by diabetes is
underreported because of the other associated complications, such as cardiovascular
disease. Diabetes is estimated to affect 25.8 million people, or 8.3%, of the U.S.
population. Of major concern is that 18.8 million of these people are diagnosed, whereas
7.0 million people remain undiagnosed. Worldwide, diabetes affected 246 million people
in 2007, and this figure is predicted to increase to a startling 366 million by 2030 (Setacci
et al., 2009). Diabetes is a debilitating disease and is the leading cause of kidney failure,
new cases of blindness, heart disease, and stroke. It is also a major cause of nontraumatic lower limb amputation among adults in the United States due to failure of
chronic wounds to heal. Therefore, it is vital that a better understanding of the disease,
its treatment, and its prevention are explored.

1.1.1 Diabetes: insulin and glucose regulation
Throughout the day, an individual’s blood glucose levels fluctuate depending on
various factors. For example, the time of day, what has been eaten, how much food has
been consumed, and the level of physical activity will all affect a glucose measurement.
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In general, diabetics are classified as having a fasting glucose level of greater than 126
mg/dL (7 mM) (hyperglycemia). This value was lowered from a higher threshold of 140
mg/dL (7.8 mM) in 1997. In contrast, normal glucose levels are between 70-110 mg/dL
(3.9-6.1 mM). In the pre-diabetic state, fasting blood glucose levels range between 110125 mg/dL (6.1-6.9 mM).
Insulin is a hormone produced by the β-cells of the pancreas and is necessary for
converting sugars into energy used by the body. It is crucial for maintaining glucose
homeostasis and for regulating carbohydrate, lipid, and protein metabolism (Saltiel and
Kahn, 2001). Insulin binding to its receptor regulates a wide variety of biological
responses (Goldfine, 1987; White and Kahn, 1994). When glucose increases in the
blood, insulin causes the liver to convert glucose into glycogen through a process called
glycogenesis. Insulin also stimulates cells to take up glucose from the glucose transporter
type 4 (GLUT4) transporter, an insulin-regulated transporter found in adipose tissue and
striated muscle (Krook et al., 2004; Leney and Tavare, 2009). GLUT4 is responsible for
transporting glucose into the cell, leading to a decrease in blood sugar (Leney and Tavare,
2009; Leto and Saltiel, 2012; Stockli et al., 2011). When insulin levels are low, GLUT4
is contained in vesicles located inside muscle and fat cells (Stockli et al., 2011). Binding
of insulin to the insulin receptor leads to activation of the receptor’s tyrosine kinase
domain (Klip, 2009; Krook et al., 2004). Upon receptor phosphorylation and recruitment
of insulin receptor substrate (IRS-1), a signaling cascade is activated, which results in
GLUT4 expression on the plasma membrane. This then allows the passive diffusion of
glucose down its concentration gradient into the cell. Once inside the cell, glucose
becomes phosphorylated to glucose-6-phosphate, which maintains the concentration
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gradient necessary for the continued passage of glucose into the cells. Glucose-6phosphate can undergo glycolysis for energy production or is polymerized into glycogen
for energy storage. Mice lacking the insulin receptor die within the first week after birth,
and disruptions in the signaling pathway are associated with severe insulin resistance
(Accili et al., 1996; Accili et al., 1999; Joshi et al., 1996; Taylor et al., 1992). Therefore,
the balance between insulin and glucose signaling is vital to prevent long term
pathological complications.

1.1.2 Diabetes: clinical effects in humans
Diabetes is classified into several types, and each type is characterized by whether
the body is able to produce/use insulin and also who is affected. Over the years, the age
at which patients become diabetic has become less of a classification factor, and the
symptoms manifested have become the more important determinant.
Type 1 diabetes affects an estimated 5-10% of diagnosed Americans. This form
of diabetes was previously called insulin-dependent diabetes mellitus (IDDM) or
“juvenile-onset” diabetes. However, an increasing number of cases are demonstrating
that type 1 can occur at any age. Symptoms include frequent urination, unusual thirst,
extreme hunger, unusual weight loss, extreme fatigue, and irritability. In this form, the
body fails to produce insulin due to the destruction of pancreatic β-cells by the immune
system. Treatment for this form includes injection of insulin into the body. There is no
known way to prevent this form of diabetes, and risk factors may be autoimmune,
genetic, or environmental. However, proper treatment and monitoring can lead to a
normal, healthy life.
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Type 2 diabetes is a heterogenous disorder characterized by decreased production
of insulin, resistance to insulin, or failure of the body to use insulin properly. The β-cells
are also unable to compensate for insulin resistance (β-cell dysfunction) (DeFronzo,
1997; Flatt, 1997). This form of diabetes was previously called non-insulin-dependent
diabetes (NIDDM) or “adult-onset” diabetes. When glucose builds up in the blood due to
failure of insulin to move sugar into the cells, it can cause two problems: 1) the cells may
be starved for energy immediately and 2) over time, high blood glucose may cause
damage to organs such as the eyes, kidneys, nerves, or heart. Most Americans who are
diagnosed with diabetes have this form, and symptoms can include those from the type 1
group as well as frequent infections (skin, gums, and bladder), blurred vision, slowhealing cuts or bruises, and tingling or numbness in the hands or feet. Factors that
contribute to the development of this form include genetics, obesity, inactivity, and diet
(Hotu et al., 2004; Pinhas-Hamiel and Zeitler, 2005). However, not all individuals who
have type 2 diabetes display symptoms. In addition, some groups have a higher risk for
developing type 2 than others, such as African Americans, Latinos, Native Americans,
Asian Americans, Pacific Islanders, and the aged population (Grinstein et al., 2003;
Krosnick, 2000).
A third form of diabetes is gestational diabetes, which occurs during pregnancy
usually around the 24th week in women who may not have had diabetes previously
(Oliveira et al., 2012). 5-10% of pregnant women have this form (~135,000 cases in the
United States each year). Often, gestational diabetes does not display symptoms, making
it crucial that women get tested during pregnancy. However, risk factors include being
overweight prior to pregnancy, a history of gestational diabetes in an earlier pregnancy,
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and a family history of diabetes (Oliveira et al., 2012). Gestational diabetes begins when
the body is not able to make and use all the insulin it needs for pregnancy (Oliveira et al.,
2012), and glucose builds up in the blood to high levels, causing hyperglycemia. The
causes are still unknown, but it is believed that hormones from the placenta that help the
baby develop are blocking the action of the mother’s insulin in her body, causing insulin
resistance. Gestational diabetes usually disappears after pregnancy.
The fourth classification of diabetes is the pre-diabetic class and is defined as an
individual having blood glucose levels that are higher than normal but are not high
enough for a type 2 diagnosis. This form affects about 57 million Americans.
The shocking knowledge that so many forms of diabetes exist and knowing that
everyone is susceptible cannot be ignored. Given that many people are already diabetic
and therefore vulnerable to the associated health impacts, it is important to both better
understand how to prevent and control diabetes and improve strategies to address health
issues associated with this debilitating disease.

1.2 The skin
As briefly discussed above, a major complication with diabetics is the failure to
heal wounds. Often these chronic wounds are found in the extremities such as the feet,
and defects in wound repair may ultimately result in amputation of the limb. The skin is
the largest organ of the body and acts as the first barrier of protection from the external
environment (Fuchs and Raghavan, 2002; McLafferty et al., 2012). It accounts for
approximately 16% of a human’s body weight, and its thickness varies depending on the
region of the body. In addition to protection, the skin has several other important
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functions. For example, it contains nerves involved with sensations such as heat, cold,
pressure, and pain, assists in body temperature regulation, and acts to prevent loss of
fluids from the body. Chronic wounds disrupt the barrier function of the skin, leading to
increased risk of infection and other complications.

1.2.1 The skin structures
There are two main layers that make up the skin – the epidermis and the dermis
(McLafferty et al., 2012). The epidermis prevents fluid loss and protects the body from
infection. It lacks blood vessels and relies on the dermis for oxygenation, nutrients, and
waste removal (McLafferty et al., 2012). The epidermis consists of four cell types –
keratinocytes, melanocytes, Langerhans cells and Merkel cells. Keratinocytes, the
predominant cell type in the epidermis, make up about 90% of the cells in the layer and
are mainly responsible for protection against the external environment. Melanocytes
make up 8% of the cells and produce the pigment melanin. Lastly, Langerhans cells are
important in the immune response, and Merkel cells are involved with the touch
sensation.
The epidermis is crucial in the reepithelialization phase of wound healing. The
epidermis is a stratified squamous epithelium comprised of proliferating basal and
differentiated suprabasal keratinocytes (Figure 1.1). In the deepest layer of the epidermis
is the stratum basale, also called the stratum germinativum, which sits above the
basement membrane (Fuchs and Raghavan, 2002). Above this basale layer are the
stratum spinosum (prickle cell layer), the stratum granulosum (granular layer), the
stratum lucidum, and the stratum corneum, which is the outermost layer (McLafferty et
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al., 2012). The epidermis renews itself through cell division starting in its deepest layer.
As cells mature, they move from the stratum basal up to the stratum corneum where the
cells are shed.

FIGURE 1.1. The epidermis. The outermost layer of the epidermis is the stratum corneum. Below
this are the stratum lucidum, the stratum granulosum, stratum spinosum, and the stratum basale. The
stratum basale layer sits above the basement membrane.

1.3 The wound healing process
Wound healing begins immediately after tissue injury and on average, takes seven
days for complete repair. However, more extreme injuries such as deep cuts or burns
may last for months or even years. The healing process is very carefully orchestrated and
involves several overlapping steps, requiring the interactions of many cell types and
growth factors (Gurtner et al., 2008; Singer and Clark, 1999). Four main stages occur
during the process of wound repair (Figure 1.2) (Singer and Clark, 1999).
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1.3.1 Phase 1: the fibrin clot
Following tissue injury, the first step consists of formation of the fibrin and
fibronectin clot created by platelet aggregation, which leads to a stop in blood loss
(hemostasis) (Gurtner et al., 2008; Janis et al., 2010; Rafehi et al., 2011). Platelets make
up the greatest number of cells present after injury and release various components into
the blood such as extracellular matrix (ECM) proteins and cytokines and growth factors
that increase cell division (Santoro and Gaudino, 2005). In addition, proinflammatory
elements from nearby blood vessels such as serotonin, prostaglandins, thromboxane,
histamine, and others all promote cell proliferation, migration, and blood vessel growth
and dilation (Hosgood, 2006; Janis et al., 2010). The fibrin clot closes the wound site to
the external environment and prevents further contamination of the wound. It also acts as
a structural support for the wound until a provisional matrix is created (Hosgood, 2006).

1.3.2 Phase 2: inflammation
The second phase of healing consists of the inflammatory response and includes
dilation of blood vessels, which allows entry of elements from the blood stream into the
wound site (Rafehi et al., 2011). Factors such as chemokines, cytokines, and
inflammatory components such as leukocytes, neutrophils, and macrophages are released
into the wound site to remove debris and prevent infection (Eming et al., 2007; Rafehi et
al., 2011). Within an hour after tissue injury, neutrophils are the predominant cell for the
first two days following injury. Neutrophils phagocytose debris, kill bacteria, and clean
the wound by breaking down damaged tissue (Kim et al., 2008; Rafehi et al., 2011).
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Monocytes are attracted into the site soon after wounding, and their levels peak 1-1.5
days after wounding. Monocytes then mature into macrophages and remove neutrophils
from the wound (Hosgood, 2006). The main role of macrophages is to phagocytose
bacteria and damaged tissue and to secrete growth factors and cytokines that promote the
proliferation phase, the third stage of wound healing (Rafehi et al., 2011).

FIGURE 1.2. The wound healing process. Healing beings with formation of the fibrin clot (1).
The second stage of healing is the inflammatory response (2), which is followed by the proliferative
phase (3). The last stage is the remodeling step (4), which lays down a stronger, more permanent
extracellular matrix.

1.3.3 Phase 3: proliferation
The proliferation phase begins 2-3 days after tissue injury. Fibroblasts enter the
wound site even before the inflammatory phase has ended and levels peak 1-2 weeks
after wounding, becoming the main cell type in the site. During the first few days after
injury, fibroblasts mainly proliferate and migrate, but they then become crucial for
9

production of a provisional ECM. Granulation tissue forms in the wound 2-5 days post
wounding and acts as temporary tissue, taking the place of the fibrin clot (Adamson,
2009). The granulation tissue covers the wound bed and contains new blood vessels,
fibroblasts, inflammatory cells, endothelial cells, myofibroblasts, and a provisional ECM.
The provisional ECM is comprised of type III collagen, fibronectin, hyaluronan,
glycoproteins, and proteoglycans. Though the collagen of the provisional ECM is not as
strong as the collagen that makes up normal, healthy tissue, it provides strength to a
wound that is otherwise held together by just the fibrin clot.
The provisional ECM also allows for migration of epithelial cells over the wound
bed to form a barrier between the wound and the external environment, a process called
reepithelialization. Reepithelialization is crucial for repair of damaged tissue and is the
focus of the studies described in Chapters 3 and 4.
Reepithelialization is imperative for wound healing because it is required to
restore barrier function (Gurtner et al., 2008). Defects would leave the open wound
vulnerable to infection and further damage. Growth factors such as platelet-derived
growth factor (PDGF), transforming growth factor beta (TGF-β), and fibronectin promote
cell proliferation, migration, and ECM production. The basal keratinocytes of the
epidermis and the appendages of the dermis, such as hair follicles and sebaceous glands,
migrate as a sheet known as the epithelial tongue (Bartkova et al., 2003). Keratinocytes
first migrate without proliferation, but eventually, cells are needed to replace the space
vacated by the migrated cells, resulting in epithelial cell proliferation at the wound edge
(Hosgood, 2006). The cells move through the damaged tissue and the matrix, and
together with proliferating epidermal and dermal cells, leads to wound closure. Once
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cells from both sides of the wound meet, migration ceases due to contact inhibition. The
cells reestablish cell-cell junctions and become anchored to the basement membrane
(Santoro and Gaudino, 2005). Basal cells then divide and differentiate to reestablish the
strata of normal healthy skin.
In addition to proliferation and reepithelialization in the proliferative phase, the
crucial step of angiogenesis, or neovascularization, also occurs. Angiogenesis is
triggered by the release of cytokines and growth factors produced by inflammatory cells,
keratinocytes, and fibroblasts (Rafehi et al., 2011). Stem cells of endothelial cells from
surrounding blood vessels migrate through the ECM to the wound to grow new vessels.
These new blood vessels deliver oxygen and nutrients into the wound site (Adams and
Alitalo, 2007; Tonnesen et al., 2000), which are required by fibroblasts and epithelial
cells. Failures in the proliferative phase can result in a chronic open wound, which may
lead to further complications.

1.3.4 Phase 4: remodeling
The last phase of healing is the remodeling phase, which begins 2-3 weeks after
injury and can last for years (Deonarine et al., 2007; Gurtner et al., 2008). The wound
contracts due to activities of growth factors, extracellular matrix proteins, integrin
receptors, and myofibroblasts (Darby and Hewitson, 2007; Desmouliere et al., 2005).
Earlier events, such as phagocytosis and cell migration, cease, and cells no longer
needed, such as endothelial cells and macrophages, undergo apoptosis or leave the wound
site. Protease secretion is suppressed, and synthesis and deposition of collagen increases.
Fibroblasts, macrophages, and endothelial cells secrete matrix metalloproteinases, which
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break down the provisional matrix, and a more permanent matrix made up of the stronger
type I collagen is created (Gurtner et al., 2008). This phase can be fragile and lead to
scarring or to formation of chronic non-healing wounds.
Chronic wounds differ from acute wounds by their inability to follow the normal
healing process. In a chronic wound, there are disturbances in the expression of growth
factors, cytokines, and proteins that assist in tissue repair. Multiple forms of chronic
cutaneous wounds exist, which include pressure, fungal, and venous wounds and diabetic
foot ulcers (Moreo, 2005; Mustoe, 2004). Depending on the severity of a wound and
form of treatment, damaged tissues may take weeks to heal. However, in many cases,
wounds may take years to fully repair if they are able to heal at all. In addition, even if a
wound successfully repairs, the tissues may never fully regain the properties of uninjured
skin.

1.3.5 Epidermal growth factor receptor and signaling in wound healing
Though there are many factors that contribute to successful wound healing, one
vital receptor is the epidermal growth factor receptor (EGFR). The EGFR is a receptor
tyrosine kinase that is important for proper development and tissue homeostasis and has
been demonstrated to be required for reepithelialization (Brem et al., 2007; Hudson and
McCawley, 1998; Stoscheck et al., 1992). In healthy tissue, expression of EGFR and its
ligands was found to transiently increase after injury (Stoscheck et al., 1992; Tokumaru
et al., 2000). In contrast, EGFR was decreased at wound margins in chronic, non-healing
wounds (Brem et al., 2007), further demonstrating an important role of EGFR in wound
healing. EGFR signaling leads to rapid and delayed responses necessary for wound
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healing, which include cytoskeleton reorganization and modulation of cell-cell contacts
necessary for migration. EGFR also affects gene expression. Of particular interest to our
studies is transcription factor Snai2/Slug.
One way that EGFR regulates reepithelialization is through the expression of
Snai2/Slug. It is a member of the Snail superfamily of transcription factors, which
encode zinc-finger proteins and function as transcriptional repressors (Cobaleda et al.,
2007; Hemavathy et al., 2000b; Shirley et al., 2010). Snai2 is a vital component of
epithelial to mesenchymal transition during embryonic development (Barrallo-Gimeno
and Nieto, 2005; Hemavathy et al., 2000a; Nieto, 2002; Sefton et al., 1998; Shook and
Keller, 2003) but has also been shown to be highly expressed in adult tissues, such as the
skin, heart, placenta, kidney, lung, and uterus (Parent et al., 2004). Snai2 has also been
demonstrated to be required for successful reepithelialization (Chandler et al., 2007;
Hudson et al., 2009; Savagner et al., 2005). Increased Snai2 expression leads to
decreased E-cadherin and β-catenin expression, which are important in adheren junctions,
and to enhanced expression of matrix metalloproteinases at wound margins (Chandler et
al., 2007). At the wound edges of normally healing canine corneal wounds, Snai2
expression was increased (Chandler et al., 2007). However, Snai2 was decreased at
margins of non-healing corneal erosions. In addition, Snai2 expression was found to be
elevated in keratinocytes at wound margins in mice as well as in keratinocytes migrating
from tissue explants ex vivo (Savagner et al., 2005). Lastly, Snai2 null mice display
decreased epithelial outgrowth from ex vivo skin explants (Kusewitt et al., 2009), and
exposure of null mice to ultraviolet radiation resulted in chronic, non-healing wounds
(Hudson et al., 2009), further demonstrating a role of Snai2 in wound repair.
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It is through the activities of EGFR and Snai2 that we believe contribute to
diabetes-impaired wound healing, as Snai2 is an essential mediator of EGFR-mediated
reepithelialization.

1.3.6 Diabetes-impaired wound healing
The normal process of wound healing requires an intricate orchestration of events.
However, with the added complication of diabetes, healing is poorly executed and
uncontrolled, resulting in chronic, non-healing wounds (Usui et al., 2008; Velander et al.,
2008). Diabetic foot ulcers are the most common cause of non-traumatic lower extremity
amputations in the world (Wu and Armstrong, 2005) and occur in up to 15% of diabetics
(Rafehi et al., 2011). Impaired wound healing is usually a consequence of macro- and
micro-angiopathy and neuropathy, and defects occur in all phases of the wound healing
process (Rafehi et al., 2011). Therefore, it is important to better understand the
underlying mechanisms of diabetic wound healing and how deficiencies can be remedied.
In diabetes-impaired wound healing, there is dysregulation in the inflammatory
response. Macrophages have impaired phagocytic function, leading to failure to remove
necrotic tissue (Khanna et al., 2010; Liu et al., 1999). Cytokine and growth factor levels
are uncontrolled, which may prolong the inflammatory phase. This then results in
delayed progression into the later phases of wound healing (Blakytny and Jude, 2009).
In the proliferation phase, reepithelialization, proliferation, and differentiation are
affected. The extracellular matrix is produced in smaller amounts, and cell migration and
adhesion to the matrix are disrupted due to covalent modification of collagen, preventing
access of a scaffold to almost all cells in the proliferative and migratory phase (Bailey et
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al., 1998; Paul et al., 1998; Peppa and Raptis, 2011). Apoptosis of fibroblasts is
increased, and migration is decreased, resulting in impaired granulation tissue formation.
In addition, keratinocyte proliferation is decreased, and cell morphology and
differentiation are altered (Al-Mashat et al., 2006; Peppa and Raptis, 2011; Spravchikov
et al., 2001). Therefore, the ability of the wound to restore a barrier against the external
environment is no longer achieved, leaving the wound vulnerable to further damage and
potential infection. In addition, levels of endothelial progenitor cells, which migrate to
the site of injury from the basement membrane, are decreased, leading to impaired
angiogenesis (Loomans et al., 2004; Tepper et al., 2002). This then leads to deprivation
of nutrients and oxygen required at the wound site, further delaying wound repair.
In addition, the regulation of growth factors, including those that promote
keratinocyte migration and angiogenesis, is impaired. Defects in cell migration may
result from decreased growth factors such as insulin-like growth factor-1 (IGF-1), which
has been demonstrated to increase wound healing in diabetic animal models (Bitar, 1997;
Tsuboi et al., 1995). Stimulation of epithelial cells is also impaired due to downregulation in factors such as EGF, PDGF, IL-8, IL-10, and TGF-β1. Matrix
metalloproteinases (MMPs) MMP-2, MMP-8, and MMP-9 are increased, and MMP
inhibitors are decreased, resulting in delayed wound healing due to the destruction of
proteins and growth factors required for normal healing (Peppa and Raptis, 2011; Yager
et al., 1996). Lastly, wound contraction is disrupted in the remodeling phase, and the
disorganized deposition of collagen in ECM formation leads to weak tissue repair and
avascular scarring (Peppa and Raptis, 2011).
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Diabetic wounds continue to be a serious life-changing complication of diabetes,
and failure to heal causes substantial morbidity due to deficits in wound repair, including
persistent ulcerations, infections, and amputations (Blakytny and Jude, 2009; Rafehi et
al., 2011). While treatments are available, they are not completely effective, and current
research is focused on developing novel therapeutic strategies for diabetic ulcers
(Blakytny and Jude, 2009; Rafehi et al., 2011).

1.4 Advanced glycation end products
Among the many issues associated with diabetes, the accumulation of advanced
glycation end products (AGEs) contribute to pathology. AGEs are the product of a
nonenzymatic reaction between reducing sugars with proteins, lipids, and nucleic acids
also called the Maillard reaction (Maillard, 1912; Peppa and Raptis, 2011; Singh et al.,
2001). This process was identified in the early 1900’s when it was observed that heating
amino acids with reducing sugars resulted in a yellow-brown color (John and Lamb,
1993; Maillard, 1912). Following an initial glycation reaction between glucose and
proteins, a Schiff base forms, followed by rearrangement to an Amadori product (Lapolla
et al., 2003) (Figure 1.3). Through a series of oxidation/reduction reactions and
rearrangements, the final products leave proteins damaged and unable to perform their
normal functions (Ahmed, 2005). AGEs are constantly formed in the body, but in the
presence of conditions such as diabetes, renal failure, Alzheimer’s disease, rheumatoid
arthritis, and aging, the rate of AGE formation is increased, and removal is decreased
(Singh et al., 2001; Takeuchi and Yamagishi, 2008; Vytasek et al., 2010). Histologically,
AGEs have been shown to accumulate in various tissues such as the renal cortex
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(Bierhaus et al., 1998), the cartilage in rheumatoid arthritis (Takahashi et al., 1994), and
cardiac muscle, lung, and liver (Sell and Monnier, 1990). Studies are establishing a
causal role of AGEs on processes such as cardiovascular disease and arthritis. For
example, AGE accumulation in the vasculature contributes to arterial stiffening in
cardiovascular disease and to stiffening of joints in arthritis, demonstrating the broad
range in which AGEs can be debilitating.
Exogenously, AGEs are ingested from the diet or through tobacco smoke and
account for ~10% of AGEs in the body. They are naturally produced in uncooked foods,
and formation is accelerated through processing such as sterilization, pasteurization, and
flavor and appearance enhancements (Peppa and Raptis, 2011). Additionally, cooking
methods such as grilling and frying also promote AGE formation and levels further
increase with higher time and degree of exposure to heat (Goldberg et al., 2004;
Luevano-Contreras and Chapman-Novakofski, 2010; Uribarri et al., 2010).
The ability of AGEs to accumulate both endogenously and exogenously in the
body makes it a dangerous factor in damaging proteins and preventing normal cell
function. These inhibitory actions also extend to impaired diabetic wound healing.

FIGURE 1.3. The Maillard reaction. Glucose and proteins react nonenzymatically to form
covalently modified proteins, which lead to protein dysfunction and impaired signaling.
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1.4.1 AGE involvement in diabetic wound repair
Because AGEs form from chemical reactions with glucose, hyperglycemia pushes
the forward reaction towards glycation, and an increasing body of evidence suggests that
AGEs and associated reactive intermediates disrupt various aspects of the wound healing
cascade (Ahmed, 2005; Huijberts et al., 2008; Peppa and Raptis, 2011; Peppa et al.,
2009). AGEs have been implicated in defective cell locomotion and survival (Loughlin
and Artlett, 2009; Morita et al., 2005; Zhu et al., 2011). In addition, exposure of rats to
the AGE precursor methylglyoxal decreased the numbers of cells actively migrating into
the wound, decreased angiogenesis, and reduced secretion and accumulation of
extracellular matrix components (Berlanga et al., 2005).
High glucose from the diet causes increased AGE levels, and dietary manipulation
of AGEs and AGE precursors in mouse models provides evidence that AGEs contribute
to the impaired wound healing observed in diabetes (Morita et al., 2005; Peppa et al.,
2009; Zhu et al., 2011). Numerous studies have shown that dietary AGEs are absorbed
and significantly contribute to the body’s AGE level and pathology (Luevano-Contreras
and Chapman-Novakofski, 2010). Restricting dietary AGE prevented atherosclerosis
(Lin et al., 2003), kidney dysfunction, type 1 and type 2 diabetes, improved insulin
sensitivity, and accelerated wound healing in animals (Peppa et al., 2003; Peppa and
Raptis, 2011). In addition, restricting dietary AGE in diabetic patients reduced markers
of oxidative stress, endothelium dysfunction and inflammation (Luevano-Contreras et al.,
2013). In diabetic db/db mice fed a high AGE diet, increased levels of the AGE
carboxymethyl lysine (CML) was present in wound tissue, and these mice displayed a
sustained inflammatory response and incomplete wound closure (Peppa et al., 2003).
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Conversely, restricting dietary AGE in diabetic mice improved wound closure compared
to those fed a high AGE diet (Peppa et al., 2003). Therefore, studies conducted in both
animals and humans demonstrate that dietary AGE significantly contributes to the body’s
AGE pool and to the complications from diabetes-related pathologies.
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Rationale
It is vital to better understand the mechanisms involved in defective wound repair
in diabetes. Diabetes entails an increase in blood glucose levels, which leads to the
accumulation of AGEs. The literature reports that hyperglycemia, AGE precursors, and
AGEs lead to impaired EGFR activity. EGFR is a crucial receptor that leads to
downstream signaling required for successful wound reepithelialization, suggesting that a
defect in EGFR signaling may be a factor in impaired diabetic wound healing.
Our goal is to further explore the impact of AGEs on EGFR signaling and
downstream targets in diabetes-impaired wound healing. The work described in this
dissertation tested the following hypothesis:

Hypothesis
AGE precursors and AGEs, which form because of hyperglycemia in diabetes,
cause a decrease in EGFR activation and downstream targets, resulting in impaired
reepithelialization (Figure 1.4).
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FIGURE 1.4. Model of AGE involvement in diabetic wound reepithelialization. Hyperglycemia
results from diabetes and reacts with proteins to form AGE precursors and AGEs. AGEs and their
precursors lead to impaired EGFR signaling and downstream function, resulting in defective wound
repair.

The specific aims to test this hypothesis are as follows:

Project Aims

Aim 1: Investigate the effects of AGE precursors and AGEs on EGFR activity and
its downstream functions in a cellular system
Hypothesis: AGE precursors and AGEs will inhibit EGFR signaling and impair migration
and proliferation in keratinocytes.
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Results: Chapter 3 (EGFR in a cellular system)

Aim 2: Evaluate Snai2 expression and wound healing in diabetic models
Hypothesis: Diabetes will lead to decreased Snai2 expression and impaired wound
healing under diabetic conditions.
Results: Chapter 4 (Snai2 in a cellular system and in ex vivo explants)

Aim 3: Determine whether modulating Snai2 expression promotes wound repair
under diabetic conditions.
Hypothesis: Promoting increased Snai2 expression will allow for recovery of wound
healing even under diabetic conditions.
Results: Chapter 4 (Snai2 in ex vivo explants)
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CHAPTER 2
Materials and Methods
The following materials and methods were used for the experiments described in this
dissertation.

2.1 Cell culture studies
The non-tumorigenic human keratinocyte cell line, SCC 12F, was kindly provided
by Dr. William A. Toscano, Jr (University of Minnesota, Minneapolis, MN). These cells
over-express the EGFR by ~5-fold relative to normal keratinocytes (Hudson and
McCawley, 1998), which is similar to what is reported at wound margins during repair
(Stoscheck et al., 1992). The SCC 12F cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) containing physiologically normal glucose levels (6 mM)
(Sigma, Saint Louis, MO), supplemented with 5% defined calf serum (DCS) (HyClone,
Thermo Scientific, Waltham, MA), 1% L-glutamine (Sigma), and 0.5% antibiotics
(penicillin, 100 units/ml, and streptomycin, 50 g/ml) (Gibco, Grand Island, NY).
HaCaT cells were provided by Dr. Mitch Denning (Loyola University Medical Center,
Maywood, IL). These cells are a spontaneously transformed, non-tumorigenic human
keratinocyte cell line (Boukamp et al., 1988). HaCaTs were maintained in medium
containing DMEM:F12 (Sigma) supplemented with 10% newborn calf serum
(Gibco/Invitrogen, Grand Island, NY), 4x MEM amino acids (Sigma), 1% L-glutamine,
and 0.5% antibiotics (penicillin, 100 units/ml, and streptomycin, 50 g/ml) as previously
described (Cooper et al., 2007). Normal human epidermal keratinocytes (NHEK) (Life
Line Cell Technology, Frederick, MD) were maintained in DermaLife K Medium
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Complete Kit (Life Line Cell Technology), a serum-free medium. SCC 12F and HaCaT
keratinocytes were cultured at 37°C in 5% CO2/95% air humidified incubators. The cells
were grown to 50-60% confluency and changed into serum-free media [6 mM glucose
DMEM containing 0.1% bovine serum albumin (BSA), 1% L-glutamine, and 0.5%
antibiotics (penicillin, 100 units/ml, and streptomycin, 50 g/ml) for SCC 12F
experiments and DMEM:F12 containing 0.1% BSA, 1% L-glutamine, and 0.5%
antibiotics (penicillin, 100 units/ml, and streptomycin, 50 g/ml) for HaCaT experiments]
overnight prior to treatments. Because NHEK medium is provided serum-free,
experiments were started as soon as ideal confluency was reached.

2.1.1 Cell culture drug treatments
To mimic a diabetic environment, either high glucose medium [25 mM glucose
DMEM (Sigma) with supplements (0.1% BSA, 1% L-glutamine, and 0.5% antibiotics
(penicillin, 100 units/ml, and streptomycin, 50 g/ml))] or the AGE precursor, glyoxal, in
low glucose media [6 mM glucose DMEM (Sigma) with supplements (0.1% BSA, 1% Lglutamine, and 0.5% antibiotics (penicillin, 100 units/ml, and streptomycin, 50 g/ml))]
was used. The reactive intermediate, glyoxal, has been demonstrated to be formed from
all stages of the glycation process (Bucala, 1997). Glyoxal leads to the AGE,
carboxymethyl lysine (CML), which was the first AGE discovered forming in vivo
(Ahmed et al., 1986; Tessier, 2010) and is used as one of the major biomarkers of the
Maillard reaction in human tissues (Thorpe and Baynes, 2002).
The stock of glyoxal (GO, Sigma) is provided at 40% in H2O (~8.8 M). The
working concentration of glyoxal was prepared by diluting the 8.8 M stock in the serum24

free medium corresponding to each cell line (Section 2.1) or in explant medium (Section
2.2.2). Cells were stimulated with 10 nM epidermal growth factor (EGF) (Biomedical
Technologies, Stoughton, MA) reconstituted in Minimum Essential Medium Eagle
(Sigma) with supplements [0.1% BSA, 1% L-glutamine 0.5% antibiotics (penicillin, 100
units/ml, and streptomycin, 50 g/ml), and 1% sodium pyruvate (Sigma)] for the times
indicated in the figure legends prior to protein collection. For experiments involving the
glycation inhibitor, aminoguanidine hydrochloride (AG, Sigma, > 98% crystalline), cells
were pre-treated with 5 mM AG made up in 0.1% BSA/6 mM glucose DMEM for 6 h
before the addition of glyoxal, and AG was present for the duration of the experiment.
To pharmacologically induce Snai2 protein, tetracycline hydrochloride (Sigma) dissolved
in sterile water was added to the cells with a final concentration of 10 µM, and
transforming growth factor beta (TGF-β) (Millipore, Billerica, MA) reconstituted in
sterile water was given to the samples at a final concentration of 10 ng/ml. Keratinocytes
and explants were exposed to the chemicals for a maximum of 5 d.

2.1.2 MTS proliferation assay
8x103 cells of SCC 12F cells were plated into a 96-well plate. The next day, the
keratinocytes were serum-starved in 0.1% BSA/6 mM glucose DMEM overnight. The
cells were then treated with 0.5 mM glyoxal made up with serum-free medium for 24 h
and stimulated with 1 nM EGF for 2 or 24 h to promote cell proliferation. At the end of
the treatment period, the medium in the wells was removed and replaced with fresh
medium to remove cellular debris. 20 µl of the solution (3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS) / (phenazine
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methosulfate; PMS) [PMS (Pierce) - 0.92 mg/ml in Dulbecco’s PBS; MTS (Promega,
Madison, WI) - 2 mg/ml in Dulbecco’s PBS; MTS/PMS solution – 100 µl PMS in 2 ml
MTS] was added to each well and incubated for 1.5 h at 37ºC while shaking. Results
were then read at 490 nm with the SpectraMax 340 (Molecular Devices, Sunnyvale, CA).

2.1.3 Boyden chamber migration assay
2x104 cells of SCC 12F cells were plated into inserts of a 24-well companion
plate (Becton Dickinson, Franklin Lakes, NJ). Keratinocytes were allowed to adhere for
2 h and then treated with 0.5 mM glyoxal diluted in 0.1% BSA/6 mM glucose DMEM
and to 1 nM or 10 nM EGF for 24 h to promote cell migration. At the end of the 24 h
incubation period, the insides of the inserts were wiped clean with a cotton swab. They
were then fixed in ice-cold 100% methanol and stained with 0.2% crystal violet (Sigma)
in water for 5 min. The membranes of the inserts were removed and mounted onto glass
slides using VectaShield with 2 µg/mL DAPI (Vector Labs Inc., Burlingame, CA).
Treatment groups were performed in triplicate, and images were obtained using the
Olympus IX70 inverted fluorescence microscope (Olympus, Center Valley, PA) and a
10x objective with 4 fields per membrane. DAPI-stained cells were counted to determine
the number of migrated cells.

2.1.4 Immunoblot analysis
Cells were rinsed in ice-cold phosphate-buffered saline (PBS) (137 mM sodium
chloride, 2.7 mM potassium chloride, 4.3 mM sodium phosphate dibasic heptahydrate,
and 1.5 mM potassium phosphate monobasic, pH 7.2) and harvested in Radio Immuno
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Precipitation Assay (RIPA) buffer (50 mM Tris pH 7.4, 1% NP40, 0.25% sodium
deoxycholate, 150 mM sodium chloride, 1 mM ethylenediaminetetraacetic acid (EDTA),
1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 mM sodium
fluoride, 1 µg/mL pepstatin, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 10 mM sodium
pyrophosphate, and 10 mM -glycerophosphate). Cell lysates were sonicated using the
Sonifier Cell Disruptor 200 (Branson Ultrasonics Corporation, Danbury, CT) with an
output control of 5 and duty cycle 30%. Extracts were clarified by centrifugation (14,000
RPM, 4 min, 4ºC) in the Centrifuge 5417R (Eppendorf, Hauppauge, NY), and the
supernatant was collected for protein analysis. Protein quantification was performed
using the BCA protein assay (Pierce, Rockford, IL). 20 μg of protein was separated by
electrophoresis through a 7.5% SDS-polyacrylamide gel for detection of carboxymethyl
lysine (CML) or phosphotyrosine, and 50 µg of protein was separated in a 12% gel for
Snai2. Proteins were transferred overnight to polyvinylidene difluoride membrane for
CML and phosphotyrosine and to nitrocellulose for Snai2. Membranes were blocked in
either 3% BSA/Tris-buffered saline-Tween 20 (TBS-T) or 5% milk/TBS-T for 1 h and
were probed overnight with antibodies for CML (Abcam, Cambridge, MA) 1:2,500
diluted in 3% BSA, phosphotyrosine (Millipore) 1:2,000 diluted in 3% BSA/TBS-T,
Snai2 (Cell Signaling, Danvers, MA) 1:500 diluted in 3% BSA/TBS-T, and β-Tubulin
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) 1:500 diluted in 5% milk/TBS-T
(Table 2.1). Membranes were washed with 1x TBS-T and incubated with an anti-rabbit
secondary antibody (Promega) 1:5,000 for CML and β-Tubulin and 1:10,000 for Snai2,
and with an anti-mouse secondary antibody (Promega) 1:2,500 for phosphotyrosine in the
respective blocking agents for 1 h at room temperature. Membranes were washed in 1x
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TBS-T and developed using the SuperSignal chemiluminescent detection system (Pierce).
Immunoblot results were imaged using a Digital Science Image Station on a Kodak
440CF Imager (Kodak, New Haven, CT). A region of interest was selected around the
largest band on the membrane, and the box was replicated over the remaining bands. The
intensity of the perimeter of the box was identified as the background, and the value of
this intensity was subtracted from the total intensity measured in each of the regions of
interest. This yielded the densitometry measures of the immunobands.

TABLE 2.1. Summary of specific western blot conditions
Primary
Antibody

Dilution

Block

Membrane

Secondary
Antibody

Dilution

β-Tubulin
Santa Cruz #sc-9104

1:500

5%
milk/TBS-T

Nitrocellulose/
PVDF

Anti-Rabbit
Promega
#W401B

1:5,000

CML
Abcam #ab27684

1:2,500

3%
BSA/TBS-T

Nitrocellulose

Anti-Rabbit

1:5,000

EGFR
Santa Cruz #sc-03

1:1,000

5% milk

PVDF

Anti-Rabbit

1:10,000

GAPDH
Chemicon #MAB374

1:300

5% milk

Nitrocellulose

Anti-Mouse
Promega
#W402B

1:5,000

PARP
Cell Signaling #9542

1:1,000

5% milk

Nitrocellulose

Anti-Rabbit

1:2,000

Phosphotyrosine
Millipore #05-1050

1:2,000

3% BSA

PVDF

Anti-Mouse

1:2,500

Sp1
Cell Signaling #5931

1:1,000

3% BSA

Nitrocellulose

Anti-Rabbit

1:1,000

Snai1/Snail
Abcam #17732

1:1,000

3% BSA

Nitrocellulose

Anti-Rabbit

1:20,000

Snai2/Slug
Cell Signaling #9585s

1:500

3% BSA

Nitrocellulose

Anti-Rabbit

1:10,000
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2.1.5 RNA isolation and quantitative real-time PCR (qRT-PCR)
RNA was isolated from SCC 12F cells by first washing cells with PBS and then
incubating the cells with TRIzol reagent (Invitrogen) for 10 min at room temperature.
Using a cell scraper, the samples were collected into a microcentrifuge tube and vortexed.
RNase-free chloroform was added to each sample, vortexed, and allowed to sit for 3 min.
The samples were then clarified by centrifugation (14,000 RPM, 10 min, 4°C) in the
Centrifuge 5417R (Eppendorf). The aqueous phase was collected into a new microfuge
tube, and the samples were incubated with RNase-free isopropanol for 10 min at room
temperature to precipitate RNA. The samples were then centrifuged (14,000 RPM, 10
min, 4°C), and then the supernatant was collected. RNase-free 70% ethanol was used to
wash the pellet, and then the samples were centrifuged once more (14,000 RPM, 5 min,
4°C). The supernatant was discarded, and the remaining pellet was air-dried for 5 min,
followed by resuspension in RNase-free water.
The RNA was quantified using the NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies, Inc., Wilmington, DE). The High Capacity cDNA reverse
transcription kit (Applied Biosystems, Life Technologies, Carlsbad, CA) was used to
make cDNA from 2 µg RNA, and Mastermix made according to manufacturer’s protocol
(10x RT buffer, 100 mM dNTP Mix, 10x random primers, Multiscribe RT, and RNasefree water) was added to each tube. The samples were run in the PTC-200 Peltier
Thermal Cycler (MJ Research, Ramsey, MN) with the following conditions: 25°C for 10
min, 37°C for 2 h, hold at 4°.
The cDNA was diluted 1:5, and 2 µl was used for quantitative real-time PCR.
PCR reactions were run in a 384-well plate with a total volume of 10 µl containing
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cDNA product, Syber Green PCR mastermix (Applied Biosystems), and primers (final
concentration 0.2 µM). Primers were purchased from Qiagen (Germantown, MD) and
consisted of the following:
QuantiTect primer QT00044128 (Snai2 119 bp)
QuantiTect primer QT01192646 (GAPDH 119 bp)
The samples were run in the real time machine 7900HT Fast Real Time (Applied
Biosystems) with the following conditions (Xiong et al., 2005): 95°C for 10 min, 40
cycles of 95°C for 30 s, 56°C for 40 s, and 72°C for 30 s. The relative quantification of
the target gene was determined using the 2-ΔΔCt method described by (Livak and
Schmittgen, 2001).

2.1.6 Immunoprecipitation
Immunoprecipitation was carried out according to the immunoprecipitation and
crosslinking protocols as described by Invitrogen. Briefly, Snai2 antibody (Cell
Signaling) diluted in PBS/0.02% Tween 20 pH 7.4 was incubated with 50 µl Dynabeads
Protein G (Invitrogen) for 30 min at room temperature while rotating. The Dynabeadantibody complex was washed and crosslinked with 5 mM
Bis(sulfosuccinimidyl)suberate (BS3) (Thermo Fisher Scientific Inc., Waltham, MA)
diluted in Conjugation Buffer [20 mM sodium phosphate, 0.15 M sodium chloride (pH 79)] for 30 min while rotating at room temperature. The crosslinking reaction was
quenched by addition of BS3 Quenching Buffer (1 M Tris-HCl, pH 7.5) for 15 min. The
Dynabeads were then washed 3x in phosphate-buffered saline - Tween 20 (PBS-T), and
the beads were retained in the tube by a magnet. 1250 μg protein was brought up to 600
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µl with RIPA collection buffer (Section 2.1.4) and added to the Dynabeads-antibody
complex. The mixture was incubated for 3 h at 4°C while shaking. The Dynabeadsantibody-antigen complex was washed 3x in PBS and resuspended in 20 µl loading
buffer (3x, 187.5 mM Tris-HCl, pH 6.8, 6% (w/v) sodium dodecyl sulfate (SDS), 30%
glycerol, 150 mM dithiothreitol, and 0.03% (w/v) bromophenol blue). The samples were
heated at 100°C for 5 min to remove the protein from the Dynabeads, and using the
magnet to retain the beads in the tube, the supernatant was loaded into wells of a 12%
gel. Immunoblotting for CML and Snai2 was performed as described above (Section
2.1.4) (Figure 2.1).

FIGURE 2.1. Immunoprecipitation of Snai2 protein. SCC 12F keratinocytes were treated with 10
nM EGF for 24 h to stimulate Snai2 protein. Snai2 was immunoprecipitated and detected by
immunoblotting.

2.2 Animal studies
Studies involving animals were conducted according to the guidelines for the use
and care of laboratory animals of the Institutional Animal Care and Use Committee under
the University of New Mexico protocol #10-100483-HSC. FVB mice (Taconic, Hudson,
NY) were used for all studies.
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2.2.1 Transgenic mice
Snai2/Slug transgenic mice were created in the lab of Dr. Donna F. Kusewitt.
Snai2 cDNA was cloned into a keratin 5 expression vector kindly provided by Dr. Jose
Jorcano and injected into pronuclei of FVB mice. DNA was isolated from tail tips by
overnight incubation of the tails with genomic lysis solution (20 mM Tris-Cl, pH 8.0, 50
mM NaCl, 100 mM EDTA, pH 8.0, and 1% SDS) and with 0.133 mg/ml Proteinase K
(Invitrogen) in a 55°C incubator while shaking. The next day, the samples were cooled
to room temperature. Protein Precipitation Solution (Qiagen) was added to each sample.
The samples were cooled on ice for 5 min and then clarified by centrifugation (14,000
RPM, 5 min, 4°C) in the Centrifuge 5417R (Eppendorf). The supernatant containing the
DNA was removed to a new microfuge tube, and 100% isopropanol was added to the
sample and inverted until DNA precipitated out of solution. The samples were then
centrifuged (14,000 RPM, 2 min, 4°C), and the supernatant was discarded. 70% ethanol
was added to the DNA to wash the pellet, and then the samples were centrifuged (14,000
RPM, 1 min, 4°C). The ethanol was discarded, and the DNA pellet was air-dried over ice
for 15 min. The DNA was resuspended in TE buffer (10 mM Tris-HCl and 1 mM
EDTA, pH 8.0) and allowed to hydrate overnight at 4°C.
The following day, the amount of DNA in each sample was ascertained using the
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Inc.), and 20 ng DNA
was calculated for use in the PCR reaction. The GoTaq® Flexi DNA Polymerase kit
(Promega) was used according to manufacturer’s instructions for PCR. PCR
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amplification was performed using primers that produce amplicons specific for the K5Snai2 transgene. Primer sets were as follows:
β glob F: 5’-TGCTGTCTCATCATTTTGGC-3’
Snai2 R: 5’-GCATTCTGTTTGAGTAAACACTGG-3’.
Amplifications were carried out on a PTC-200 Peltier Thermal Cycler (MJ
Research) with the following conditions: 95°C for 4 min, 40x (95°C for 30 sec, 60°C for
30 sec, 72°C for 60 sec), 72°C for 10 min, hold at 4°C. The PCR products were run
through a 2% agarose gel containing SYBR Safe DNA Gel Stain (Invitrogen) at
1:10,000. A band located at ~920 bp indicated a Snai2 over-expressing mouse (Figure
2.2A).
The K5 Snai2 transgenic mice are smaller in size compared to wild type mice, and
differences in the skin include hyperkeratosis, increased follicular density, and more
active hair growth (Figure 2.2B) in the over-expressing mice.
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FIGURE 2.2. K5 Snai2 transgenic mice. (A) The presence of a band at ~920 bp indicates a Snai2
over-expressing animal. (B) FVB Snai2 over-expressing mice are smaller in size compared to wild type
littermates, have hyperkeratosis, increased follicular density, and more active hair growth. Mice shown
above are ~21 days old. The coin was provided for sense of scale.

2.2.2 Epithelial outgrowth
FVB mice aged 7 weeks were euthanized by first CO2 inhalation followed by
cervical dislocation. The hair from the dorsal side was shaved, and Nair (Church &
Dwight Co., Inc. Princeton, NJ) was used to remove the stubble (Figure 2.3A). The Nair
was rinsed off with water, and the skin was cleaned with iodine and 70% ethanol. The
skin was then dissected out and placed dermal side down onto a glass plate. Using a 3.5
mm disposable biopsy punch (Miltex, Inc., York, PA), four circular skin explants were
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isolated per animal and plated into wells of a 4-well chamber slide (Nalge Nunc
International, Rochester, NY). Following a 1 h incubation at room temperature, the
explants were submerged in 75 µl of explant medium (Mazzalupo et al., 2002). The
medium composition was as follows: DMEM (Invitrogen) and DMEM:F12 (Sigma)
powder were dissolved according to manufacturer’s instructions, and pH’ed to 7.0.
DMEM and DMEM:F12 were combined in a 1:1 (v/v) mixture and supplements were
added [10% fetal bovine serum (Invitrogen), 0.1 mM cholera toxin (Sigma), 10 ng/ml
EGF (Biomedical Technologies), 2 nM Triiodothyronine (Sigma), 2.5 µg/ml transferrin /
5 µg/ml insulin (Invitrogen), 0.4 µg/ml hydrocortisone (Sigma), 60 µg/ml
penicillin/streptomycin (Sigma), 25 µg/ml gentamicin (Sigma)]. Explants were cultured
overnight in 95% air/5% CO2 humidified incubators at 37°C. The following day, an
additional 425 µl of medium was added to each explant and incubated for another 24 h.
Explants were exposed to 0.1, 0.3, or 0.5 mM glyoxal or to 10 ng/ml TGF-β (Millipore)
diluted in explant medium for up to 5 d. Images of explants were taken on days 0, 1, 3,
and 5 from the start of glyoxal/TGF-β treatment using 4x (quantitative analysis) and 10x
(qualitative analysis) objectives and phase contrast microscopy on the Olympus IX70
inverted microscope (Olympus) (Figure 2.3B). Epithelial outgrowth was measured by
selecting the area of keratinocyte outgrowth around the explant and using the Olympus
software DP2-BSW-E-V2.2 to determine the area (µm2).
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FIGURE 2.3. Ex vivo explant collection. (A) Mice were euthanized, and the skin was cleared of hair
and removed from the dorsal side. Biopsy punches were used to isolate 3.5 mm-sized explants, and the
tissues were plated into 4-well chamber slides. Treatments were given for as long as 5 d, and epithelial
outgrowth was measured by selecting the region of cells around the tissue (red lines) and using
computer software analysis to determine outgrowth area (µm2) (B).

2.2.3 Immunocytochemistry
At the end of the incubation period, media from explants were removed by
aspiration, and explants were washed briefly in ice cold PBS. The PBS was removed and
explants were fixed in 3.7% paraformaldehyde for 15 min at room temperature while
gently shaking. The paraformaldehyde was then removed, and the explants were briefly
rinsed in PBS followed by three more washes in PBS for 10 min each while shaking.
After the second PBS wash, the explants were carefully dissected away from the cells
using a straight teasing surgical needle and fine forceps, leaving the ring of epithelial
cells in the wells. The cells were then permeabilized with 0.2% Triton-X-100 in PBS for
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10 min. Non-specific binding was blocked by incubating keratinocytes with 0.2% fish
skin gelatin (Sigma)/PBS for 1 h at room temperature. Primary Snai2 antibody (Cell
Signaling) was prepared in blocking solution at a dilution of 1:100. The blocking
solution was replaced with the primary antibody, and the samples were incubated
overnight at 4°C while shaking. The following day, the outgrowths were washed with
TBS-T 3x 10 min each. Secondary goat antibody to rabbit IgG (FITC) (Abcam) was
added to the samples 1:1,000 in blocking solution and wrapped in foil to protect from
light. The explants were incubated for 1 h at room temperature while shaking and then
washed with 0.1% Triton-X-100/5 mg/ml BSA/ PBS 3x for 5 min each. A fourth wash
was performed in TBS-T for 10 min, and a fifth containing 0.75 µg/ml DAPI
(Calbiochem, Billerica, MA) in TBS-T was performed for 15 min. The samples were
then mounted with VectaShield without DAPI (Vector Labs, Inc.) and sealed with nail
polish for storage.
The explant outgrowths were imaged using a DSU Olympus IX81 inverted
microscope (Olympus) and Stereo Investigator software (MBF Bioscience, Williston,
VT). 2D confocal montages of the outgrowths were created using a 20x objective and
saved as “mbf.jpg2000” images. The files were then converted to “.tiff” format using Fiji
imaging software (Schindelin et al., 2012). The images were opened with SlideBook
imaging software (Intelligent Imaging Innovations, Denver, CO), and a DAPI mask was
set at a low threshold of 7500. Using the DAPI image, objects (nuclei) were identified as
having a minimum of 25 pixels in a cluster. Snai2 staining (FITC) was evaluated by
measuring the mean intensity of the green within each of the objects (nuclei) identified.
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The sum of the mean FITC intensities in all the objects (nuclei) was evaluated and
normalized to the total number of objects to determine the mean intensity per cell.

2.2.4 TUNEL staining
TUNEL staining was performed using the DeadEnd Fluorometric TUNEL System
(Promega). Tissue explants from wild type mice were isolated and cultured as described
in Section 2.2.2 and exposed to 0.5 mM glyoxal made up in explant medium for 5 d or to
100 µM Etoposide (Trevigen Inc., Gaithersburg, MD) as the positive control for 6 h prior
to the end of the experiment. At the end of the test period, explants were fixed in 3.7%
paraformaldehyde/PBS, pH 7.4 for 25 min at 4°C. The skin tissues were then dissected
away, and the remaining cells were washed 2x in PBS for 5 min each at room
temperature. The cells were permeabilized with 0.2% Triton X-100/PBS for 5 min and
then washed again in PBS for 5 min at room temperature. Equilibration Buffer provided
by the kit was then added to each sample and incubated at room temperature for 10 min.
rTdT Incubation Buffer (Equilibration Buffer, Nucleotide Mix, and rTdT Enzyme) was
prepared as described by manufacturer’s instructions and added to each sample. Cells
were covered with Plastic Coverslips provided in the kit to ensure even distribution of the
reagent and to prevent the cells from drying and were then incubated at 37°C for 1 h to
allow the tailing reaction to occur. Plastic Coverslips were removed, and the reaction
was terminated by the addition of 2X SSC solution provided by the kit for 15 min at
room temperature. The samples were washed with PBS 3x for 5 min each to remove
unincorporated fluorescein-12-dUTP and then mounted with VectaShield with DAPI
(Vector Labs, Inc.) to stain nuclei. The cells were then imaged at 4x using the Olympus
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IX70 inverted fluorescence microscope (Olympus) and the Olympus software DP2-BSWE-V2.2. Fluorescein-12-dUTP incorporation resulted in green fluorescence within the
nuclei of apoptotic cells.

2.2.5 Epidermal protein isolation
Wild type and Snai2 overexpressing mice were euthanized as discussed above
(Section 2.2.2). Skin from the dorsal side of mice was removed and placed in PBS over
ice until all samples were collected. The skin was draped dermal-side down over 500 µl
of 0.25% trypsin-EDTA (Gibco) and incubated at 37°C for 30 min. The tissue was then
placed dermal-side up. With forceps, the dermal tissue was removed by scraping and
peeling it away from the epidermal layer, leaving the semi-transparent epidermal layer.
A 1 cm2 piece of tissue was placed into RIPA collection buffer as discussed above
(Section 2.1.4), and the remaining skin was placed back into PBS and stored at -80°C.
The 1 cm2 samples were homogenized with the Power Gen 125 tissue homogenizer with
a #5 setting (Thermo Fisher Scientific Inc.) and then clarified by centrifugation (14,000
RPM, 4 min, 4ºC) in the Centrifuge 5417R (Eppendorf). The supernatant was collected,
and the protein was analyzed via BCA protein assay and immunoblot as discussed above
(Section 2.1.4). 75 µg protein was calculated for analysis in the immunoblot detection
for Snai2.

2.3 Statistical analysis
Densitometry readings from the immunoblots were analyzed using one-way
Analysis of Variance (ANOVA) followed by Tukey’s post-test. Student’s t-test was used
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to compare densitometry of wild type and over-expressing mice protein levels. Cell
proliferation and migration assays and explant outgrowths were analyzed using a twoway ANOVA followed by Bonferroni’s post-test. Statistical analyses and data plotting
were performed using GraphPad Prism version 5 for Windows (GraphPad Software, San
Diego, CA). Error bars are defined as the mean +/- standard error of the mean (SEM).
Values of p<0.05 were considered statistically significant.
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CHAPTER 3
Epidermal growth factor receptor signaling and downstream function
are impaired under diabetic conditions
3.1 Introduction
Wound repair is a complex process that involves the coordination of many
elements including the release and action of growth factors and cytokines. A crucial
component of healing is the epidermal growth factor receptor (EGFR) also known as
ErbB1. This receptor is part of the ErbB family of receptor tyrosine kinases, which in
addition to EGFR, include ErbB2, ErbB3, and ErbB4 (Danielsen and Maihle, 2002).
EGFR, ErbB2, and ErbB3 are expressed in human skin with EGFR being demonstrated
as the dominant receptor (Schneider et al., 2008; Stoll et al., 2001). Once activated, these
receptors homo- and heterodimerize to induce cell signaling and function (Bazley and
Gullick, 2005; Werner and Grose, 2003).
The EGFR is a receptor tyrosine kinase located on the plasma membrane and is
important for proper development and tissue homeostasis (Bazley and Gullick, 2005;
Schneider et al., 2008). Several ligands activate the EGFR, including epidermal growth
factor (EGF), transforming growth factor alpha (TGF-α), heparin-binding EGF-like
growth factor (HB-EGF), amphiregulin, and epiregulin (Pastore et al., 2008). Activation
of the EGFR leads to several signaling pathways, which include the ERK pathway (cell
migration, proliferation, and survival), PI3K/AKT pathway (protein synthesis and cell
survival), and the JAK/STAT pathway (cell survival) (Figure 3.1) in addition to others.
In the following studies, we focused on the binding of EGF ligand and subsequent
activation of ERK, which is required for cell migration and proliferation.
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FIGURE 3.1. EGFR signaling in wound healing.
Binding of a ligand such as EGF leads to
dimerization and autophosphorylation of the
receptors. This leads to activation of signaling
cascades required for proper cell migration,
proliferation, and overall cell survival.

There is much evidence demonstrating the importance of EGFR in
reepithelialization (Hudson and McCawley, 1998). For example, expression of EGFR
transiently increases after wounding in mice and humans (Schaffer and Nanney, 1996;
Stoscheck et al., 1992; Wenczak et al., 1992) and decreases at the wound margins in
chronic, non-healing wounds (Brem et al., 2007). Abnormal EGFR function leads to
tumorigenesis (Casanova et al., 2002; Karashima et al., 2002), and down-regulation of
the receptor rapidly results in cellular proliferation and differentiation defects, impaired
wound healing, lesion development, and hair follicle defects (Hansen et al., 1997; Maklad
et al., 2009; Repertinger et al., 2004). In addition to increased edema, erythema, and
eschar, EGFR null mice demonstrated contractile function impairments during healing
and overall delayed wound closure compared to wild type mice (Repertinger et al., 2004).
EGFR promotes epithelial proliferation early in wounding (Nakamura et al., 2001;
Repertinger et al., 2004) as well as regulates acute inflammation by suppressing
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neutrophil and enhancing mast cell populations after wounding (Repertinger et al., 2004).
Lastly, though the EGFR was shown to be required for wound-induced angiogenesis, and
healing was delayed in null mice, complete tissue repair was eventually observed even in
the absence of the receptor (Repertinger et al., 2004), suggesting that the EGFR is a main
contributor but not the only mechanism for successful wound healing. In addition, there
is evidence that hyperglycemia impairs EGFR activity. When cells are exposed to high
glucose, EGFR signaling is blunted in corneal epithelial cells and in fibroblasts (Obata et
al., 1998; Xu et al., 2009). Taken together, these studies demonstrate that the EGFR is an
important part of successful wound repair, and that inhibition or abnormal receptor
activity, such as that caused by hyperglycemia, may lead to defective healing.
Though much research supports the crucial role of the EGFR in wound healing, it
is also important to recognize the contribution of EGFR ligands in tissue repair (Werner
and Grose, 2003). The earliest of these reports came from analysis of wound fluid when
EGF-like elements were found to act as chemoattractants for endothelial cells in rats
(Grotendorst et al., 1989). In addition to EGF, it has been shown that TGF-α and HBEGF stimulate the EGFR and promote keratinocyte migration and proliferation
(Repertinger et al., 2004; Tokumaru et al., 2000). Furthermore, when chronic diabetic
foot ulcers were topically treated with EGF, they achieved 76% complete healing of the
wounds (Hong et al., 2006), further demonstrating the significance of both EGFR and its
ligands in wound healing and diabetes.
Hyperglycemia caused by diabetes leads to the formation of advanced glycation
end products (AGEs), and there is evidence that identify AGEs as culprits in diabetesimpaired wound healing (Morita et al., 2005; Peppa et al., 2009; Zhu et al., 2011) as
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discussed in Chapter 1. There is also evidence demonstrating the inhibitory effect of
AGE precursors, glyoxal and methylglyoxal, on EGFR activation in umbilical vein
endothelial cells (Portero-Otin et al., 2002). However, other than the few studies
investigating the relationship between AGEs and EGFR (Cai et al., 2006; Chen et al.,
2010; Portero-Otin et al., 2002), little is known about the functional outcome of EGFR
glycation on wound healing with keratinocytes. Therefore, we explored activation of the
receptor and subsequent cell function in human keratinocytes following exposures to
AGE precursor glyoxal.

3.2 Materials and Methods
Squamous cell carcinoma cells (SCC 12F) cells, HaCaT cells, and normal
keratinocytes were used in the following experiments. These keratinocytes were exposed
to glyoxal and stimulated with EGF. Assays used to assess cell signaling and function
include the following:
Section 2.1 – Cell culture
Section 2.1.1 – Cell culture drug treatments
Section 2.1.2 – MTS proliferation assay
Section 2.1.3 – Boyden chamber migration assay
Section 2.1.4 – Immunoblot analysis
Section 2.2 – Animal studies
Section 2.2.2 – Epithelial outgrowth
Section 2.2.4 – TUNEL staining
Section 2.3 – Statistical analysis
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3.3 Results
High glucose impairs EGF-stimulated keratinocyte migration
Because studies have reported defective cell migration in the presence of high
glucose (Obata et al., 1998; Xu et al., 2009), the ability of keratinocytes to migrate in the
presence of high glucose was tested with the squamous cell carcinoma cells (SCC 12F), a
human keratinocyte cell line. Cells maintained in either 6 mM glucose or 25 mM glucose
were plated into inserts of a 24-well companion plate (Section 2.1.1 and 2.1.3). After
stimulation with EGF, cell migration was measured by counting cells that crossed the
membrane inserts and that were stained with DAPI (Section 2.1.3). Exposure of high
glucose to SCC 12F cells resulted in impaired cell migration even with EGF stimulation
(Figure 3.2), demonstrating the inhibitory effect of high glucose on EGFR activity.

FIGURE 3.2. Keratinocyte migration is impaired when exposed to high glucose. The Boyden
chamber migration assay demonstrated that exposure of keratinocytes to chronic high glucose
impaired 24 h EGF-stimulated cell migration. Purple bars = low glucose (6 mM). Blue bars = high
glucose (25 mM). Results are representative of one experiment.
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Glyoxal impairs EGF-dependent keratinocyte proliferation and migration
In the presence of glyoxal and other reactive AGE intermediates, levels of
covalently modified proteins increase, leading to potential disruption of cell function
(Ahmed, 2005; Peppa et al., 2009; Thomas, 2011). To observe the effects of glyoxal on
cells, we measured EGF-stimulated cell proliferation and migration. SCC 12F cells
treated with 10 nM EGF resulted in the breakdown of cell-cell junctions and induction of
cell migration as indicative of epithelial to mesenchymal transition (EMT) (Figure 3.3).

FIGURE 3.3. Cell scattering. Exposure of SCC 12F keratinocytes to 24 h EGF induces cell
scattering. In contrast, glyoxal inhibits EGF-stimulated keratinocyte scattering.

In contrast, cells exposed to a high dose of glyoxal (0.5 mM) and stimulated with EGF
did not display cell scattering, but rather they maintained their cell-cell junctions and
remained inert. This is in agreement with studies demonstrating the impact of diabetic
elements in impaired wound healing in diabetic patients (Lan et al., 2008; Lan et al.,
2009; Spravchikov et al., 2001). EGF-dependent proliferation was inhibited by exposure
to 0.5 mM glyoxal (Figure 3.4A) as assessed by the MTS assay. As discussed above, our
data and others have reported that keratinocyte migration is decreased by high glucose
(Lan et al., 2009). Because glyoxal formation is increased under high glucose conditions,
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we tested the impact of glyoxal on EGF-stimulated migration using a modified Boyden
chamber (Brown and Bicknell, 2001; Falasca et al., 2011). EGF treatment (1 or 10 nM)
for 24 h effectively stimulated migration, whereas migration was severely impaired upon
concurrent exposure to EGF and glyoxal (Figure 3.4B). In addition, epithelial outgrowth
was measured in skin explants obtained from 7 wk old FVB mice. Over the 5 d period,
outgrowth was detected from untreated explants and a dose dependent inhibition of
outgrowth was evident in all explants exposed to varying glyoxal doses (0.1–0.5 mM
GO) (Figure 3.4C and 3.4D).
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FIGURE 3.4. Glyoxal impairs cell proliferation and migration. (A) Proliferation of SCC 12F
keratinocytes measured following 24 h 0.5 mM glyoxal (GO) and stimulation with 2 or 24 h 1 nM EGF.
(B) Keratinocytes were exposed to 0.5 mM GO and to 1 or 10 nM EGF for 24 h. Cell migration
determined by counting DAPI-stained nuclei. (C) Mouse skin explants exposed to GO over 5 d.
Epithelial outgrowths observed using phase contrast microscopy. Dashed line indicates migrating front.
Scale bar equals 200 µm. (D) Outgrowths evaluated by measuring areas around explants. Results
represent minimum three independent experiments for proliferation and migration and at least eight mice
per group for explants. Error bars defined as mean +/- SEM. Two-way ANOVA and Bonferroni’s posttest demonstrate significance *p<0.05, **p<0.01, and ***p<0.001.
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Analysis of apoptosis by TUNEL staining was performed to determine if the
differences observed between untreated and glyoxal-treated explants was due to cell
death caused by glyoxal toxicity (Figure 3.5). Incorporation of fluorescein-12-dUTP
indicates fragmented DNA of apoptotic cells. Etoposide was used as a positive control
and is an anti-cancer agent that functions as a topoisomerase inhibitor (Hande, 1998). It
forms ternary complexes with DNA and the topoisomerase II enzyme and prevents religation of the DNA strands, leading to DNA strand breaks. This results in DNA
synthesis errors and leads to apoptosis. Little difference between the non-treated and
glyoxal-treated explants was observed (Figure 3.5). In contrast, the etoposide-treated
explants led to greater numbers of apoptotic cells. The data suggest that the impaired
outgrowth is not due to glyoxal-induced cell death.
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FIGURE 3.5. Effect of high glyoxal on apoptosis. Ex vivo skin explants from wild type mice were
exposed to 0.5 mM glyoxal for 5 d. Outgrowth areas were analyzed for apoptosis as indicated by
detection of fluorescein-12-dUTP incorporation (green). Glyoxal induces very little cell death
compared to non-treated cells (NT). Etoposide represents positive control of apoptosis. DAPI (blue)
represent cell nuclei. Results are representative of one experiment.

These observations in an ex vivo system further demonstrate the inhibitory effect of
glyoxal on the reepithelialization component of wound healing.

Glyoxal increases modification of proteins in keratinocytes
In the presence of glyoxal and other reactive AGE intermediates, levels of
covalently modified proteins increase. Glyoxal leads to formation of carboxymethyl
lysine (CML), the first AGE discovered in vivo (Ahmed et al., 1986; Tessier, 2010) and a
major biomarker of the Maillard reaction in human tissues (Thorpe and Baynes, 2002).
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When SCC 12F keratinocytes and HaCaT cells were exposed to varying glyoxal doses (0
to 0.5 mM) for 24 h, the CML levels increased as a function of dose as assessed by
immunoblotting (Figure 3.6A and 3.6C). CML levels also increased with time; modified
proteins were evident within 2 h of exposure to 0.5 mM glyoxal (Figure 3.6B and 3.6D).
When normal human keratinocytes were exposed to 0.5 mM glyoxal for 24 h, CML was
also detected (Figure 3.6E lane 3). To confirm that increased CML was due to glyoxal
exposure, keratinocytes were pretreated with aminoguanidine (AG), a potent inhibitor of
glycation (Brownlee et al., 1986). Preincubation with 5 mM AG for 6 h prevented CML
formation in response to glyoxal in both normal keratinocytes and in SCC 12F cells
(Figure 3.6E and 3.6F). These findings demonstrate that the AGE precursor glyoxal
promotes CML formation and protein modification in keratinocytes as indicated by the
increased number of anti-CML immunoreactive bands across the immunoblot.
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FIGURE 3.6. Glyoxal increases modified protein levels. Exposing keratinocytes to glyoxal (GO)
dose-dependently and time-dependently leads to increased AGE carboxymethyl lysine (CML) in
(A)&(B) SCC 12F keratinocytes (C)&(D) HaCaT cells (E) normal keratinocytes. Glycation
inhibitor, aminoguanidine (AG), prevents protein modification in normal keratinocytes (E) and in
SCC 12F cells (F). β-Tubulin is used as loading control. Results are representative of at least three
independent experiments.
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Glyoxal impairs EGF-stimulated tyrosine phosphorylation
Because AGE modification can disrupt protein function (Ahmed, 2005; Peppa et
al., 2009; Thomas, 2011), we next tested the effect of glyoxal on EGFR
autophosphorylation. Cells were exposed to 0.5 mM glyoxal for varying times then
stimulated with 10 nM EGF for 10 min. EGFR activation, as detected by
phosphotyrosine at 170 kDa, decreased with glyoxal incubation time (Figure 3.7A and
3.7B). A significant decrease in EGF-stimulated tyrosine phosphorylation was evident
within 4 h of glyoxal treatment, and maximal inhibition was achieved by 8 h. EGFstimulated EGFR activation was also tested in HaCaT cells exposed to 0.5 mM glyoxal,
and a trend in impaired receptor activation was observed over the 32 h time period tested
(Figure 3.7C and 3.7D). Similar impairments in EGF-stimulated phosphotyrosine were
observed when cells were acutely exposed to high glucose (25 mM) in our studies (Figure
3.7E and 3.7F) as well as in what has been previously shown (Obata et al., 1998; Xu et
al., 2009). The glyoxal-induced decrease in phosphotyrosine is not due to a reduction of
total EGFR protein levels (Figure 3.7G). The impairment of EGFR kinase activity was
due to CML formation under these conditions as EGF-stimulated tyrosine
phosphorylation was preserved in the presence of AG as demonstrated in both SCC 12F
cells (Figure 3.7H and 3.7I) and normal keratinocytes (Figure 3.7J and 3.7K). EGFR was
previously demonstrated to be covalently modified by glyoxal in endothelial cells
(Portero-Otin et al., 2002), and a similar modification may be occurring in the
keratinocytes.
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FIGURE 3.7. Glyoxal decreases EGF-stimulated EGFR activation. Keratinocytes were treated with
0.5 mM glyoxal (GO) at the indicated times, then stimulated with 10 nM EGF for 10 min. The
immunoblots and densitometries represent activation of EGFR as indicated by phosphotyrosine (PY) at
170 kDa in SCC 12F cells (A)&(B) and in HaCaT cells (C)&(D). (E)&(F) SCC 12F keratinocytes were
exposed to 25 mM glucose over 8 h and stimulated with 10 nM EGF for 10 min. PY levels were
evaluated. (G) Total EGFR protein is not affected in SCC 12F cells following GO exposures. SCC 12F
cells (H)&(I) and normal keratinocytes (J)&(K) were pretreated with 5 mM aminoguanidine (AG),
exposed to 0.5 mM GO for 24 h, then stimulated with 10 nM EGF. Lanes 6&7 and 8&9 (H) and Lanes
7&8 (J) were collected from duplicate plates as indicated. β-Tubulin was used as a loading control.
Results are representative of at least three independent experiments but two for (C)&(D) and one for
(J)&(K). Error bars are defined as mean +/- SEM. One-way ANOVA and Tukey’s post-test revealed
significance *p<0.05, **p<0.01, and ***p<0.001.
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However, it is possible that the affect observed in activated EGFR was due to a
modified EGF ligand by glyoxal. Therefore, we tested this theory by pre-incubating EGF
ligand with glyoxal for either 10 min (the length of time for EGF stimulation of EGFR)
or for 24 h (the length of time glyoxal is incubated with cells). The keratinocytes were
then exposed to these solutions and observed for effects on EGFR activation. We
observed no effects of glyoxal on the activity of EGF itself (Figure 3.8) further
demonstrating glyoxal inhibition on the EGF receptor.

FIGURE 3.8. Glyoxal does not affect EGF ligand. Pre-incubations with EGF ligand and
glyoxal (GO) were done in fresh media prior to addition to keratinocytes. EGF was still able to
stimulate EGFR regardless of the pre-incubations with GO. (A) Western blot demonstrating
changes in activated EGFR as demonstrated by phosphotyrosine (PY) detection. (B)
densitometry of western in (A) quantifying changes in protein levels. Results are representative
of one experiment.
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A lower dose of glyoxal (0.2 mM) was tested and assessed for EGF-stimulated
EGFR activation. This dose was chosen based on the observation that very low levels of
modified proteins are detected following exposure to keratinocytes for 24 h (Figure 3.6).
There was no significant effect of the low dose glyoxal on receptor activation during the
24 h time period tested (Figure 3.9). Altogether, these findings suggest that glyoxalinduced defects in EGF-stimulated EGFR activation may lead to further disruption in
downstream signaling and cellular function.

FIGURE 3.9. Low dose glyoxal has no effect on EGF-stimulated EGFR activation. SCC
12F keratinocytes were treated with 0.2 mM glyoxal for the indicated times then stimulated
with 10 nM EGF for 10 min. The immunoblot (A) and densitometry (B) represent activation
of EGFR as indicated by phosphotyrosine (PY) at 170 kDa. β-Tubulin was used as a loading
control. Results are representative of three independent experiments. Error bars are defined
as mean +/- SEM. One-way ANOVA and Tukey’s post-test did not show statistical
significance.

56

3.4 Discussion
The EGFR is a receptor that has been implicated in many signaling pathways
required for proper cell function and survival (Danielsen and Maihle, 2002; Maklad et al.,
2009; Pastore et al., 2008; Repertinger et al., 2004; Schneider et al., 2008; Werner and
Grose, 2003). However, dysfunctional regulation of the EGFR leads to damaging results
such as delayed cell migration and proliferation as in the case of wound healing
(Repertinger et al., 2004; Werner and Grose, 2003).
In patients suffering from chronic wounds, EGFR levels were decreased at the
wound margins and increased in areas adjacent to the wound site (Brem et al., 2007). In
addition, the availability of EGF is also decreased in chronic diabetic foot ulcers. Current
studies are being performed to evaluate the success of using topical and intralesional
routes of EGF administration on wounds (Tiaka et al., 2012). So far, results demonstrate
successful wound closure following EGF treatment (Fernandez-Montequin et al., 2007;
Fernandez-Montequin et al., 2009; Tuyet et al., 2009) and even greater healing when
given in combination with other therapies (Hong et al., 2006; Tsang et al., 2003).
Investigations into optimal dosing, methods of administration, and characteristics of
ulcers most likely to heal are yet to be performed to evaluate the effectiveness of
exogenous EGF on diabetic wounds (Tiaka et al., 2012).
Our early studies examined the effects of high glucose on EGFR activation and
cell migration and proliferation. We found that high glucose blunted the ability of EGF
to stimulate the EGFR in keratinocytes. Similar findings were observed in other studies
demonstrating the inhibitory effect of glucose on EGFR and its function. For example,
high glucose was shown to attenuate EGF-stimulated EGFR activation in Rat 1
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fibroblasts (Obata et al., 1998) and to impair EGFR signaling in human corneal epithelial
cells (Xu et al., 2009). In contrast, there is also evidence suggesting high glucose
promotes pancreatic cancer cell and proximal tubule cell proliferation through induction
of EGF expression and transactivation of the EGFR (Han et al., 2011; Saad et al., 2005),
demonstrating the difference in roles that glucose has on EGFR in various cells and
environments.
Because high glucose ultimately leads to formation of the AGE precursor,
glyoxal, we examined the effect of glyoxal on EGFR activation, which we expected
would disrupt effective wound healing. Though the highest dose of glyoxal tested (0.5
mM) is greater than what is found in diabetic patients (Lapolla et al., 2003), the
concentrations and times of exposure are comparable to what has been used in other
studies (Berge et al., 2007; Nass et al., 2010; Rattan et al., 2007; Sliman et al., 2010).
Inhibitory effects due to glyoxal were also still observable in lower doses and exposures
tested. Our studies demonstrated that high doses of glyoxal impair EGFR activation in
keratinocytes. EGFR has also been shown to be covalently modified by both of the AGE
precursors glyoxal and methylglyoxal (Portero-Otin et al., 2002). However, to the best of
our knowledge, there have been no further studies examining the specific residues that
are modified on the EGFR. The EGFR is located on the plasma membrane, exposing it to
potential glycation. Based off the known amino acid sequence of the EGFR, it is possible
to identify regions of the receptor that may be more susceptible to modification. Cysteine
residues have been implicated in protein glycation (Mostafa et al., 2007; Schwarzenbolz
et al., 2008). Therefore, due to the presence of the cysteine-rich regions in the ligand-
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binding domain of the EGFR (Garrett et al., 2002; Ward et al., 2007), it is possible there
is modification at these sites, leading to impairments in EGF binding to the receptor.
The EGFR regulates numerous signaling pathways including the ERK,
PI3K/AKT, and the JAK/STAT pathways, and high glucose affects receptor activation.
Because high glucose results in AGE formation, it is likely that impairments in EGFR
activation as a consequence of glycation (Portero-Otin et al., 2002) will lead to further
downstream defects in signaling and function. A possible avenue to explore is the
transcription factor Snai2/Slug. This protein down-regulates factors such as E-cadherin
and β-catenin, which are important in adheren junctions (Chandler et al., 2007). Snai2 is
also a key element in successful reepithelialization (Chandler et al., 2007; Hudson et al.,
2009; Savagner et al., 2005). Therefore, we further investigated this effector protein of
EGFR and its involvement in diabetes-impaired wound healing.
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CHAPTER 4
Glyoxal leads to defective keratinocyte migration and down-regulation
of Snai2
4.1 Introduction
Snai2/Slug is an important downstream effector of the EGFR (Chapter 3, Figure
3.1) (Velander et al., 2008). It is a member of the Snail superfamily of transcription
factors, which encode zinc-finger proteins and function as transcriptional repressors
(Cobaleda et al., 2007; Hemavathy et al., 2000b; Shirley et al., 2010) (Figure 4.1). The
Snail superfamily is characterized by a highly conserved region at the carboxy terminus
that contains four to six C2H2-type zinc fingers (Cobaleda et al., 2007; Hemavathy et al.,
2000a; Nieto, 2002). Snail family genes consist of six common bases, CAGGTG
(Cobaleda et al., 2007), and this motif makes up a subset of the E-box (CANNTG), the
conserved binding site of basic helix-loop-helix transcription factors (Hemavathy et al.,
2000a). The amino termini are less conserved, but most vertebrates contain the
conserved SNAG domain (Hemavathy et al., 2000a; Nieto, 2002). Snai2 consists of 268
amino acids in length with five zinc fingers at the carboxy terminus (Cohen et al., 1998).
Its repressive activity is thought to arise from the SNAG domain as well as through
recruitment of a corepressor, such as carboxy-terminal binding protein (CtBP-1)
(Cobaleda et al., 2007).
Snai2 is an essential zinc finger protein required for development, EMT, cell
adhesion, and cell migration (Barrallo-Gimeno and Nieto, 2005; Cobaleda et al., 2007;
Hemavathy et al., 2000a; Katafiasz et al., 2011; Nieto, 2002; Nieto et al., 1994; Sefton et
al., 1998; Shook and Keller, 2003). It was first discovered in the neural crest and
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developing mesoderm of the chick embryo (Nieto et al., 1994). However, it was also
shown to be required for successful reepithelialization (Chandler et al., 2007; Hudson et
al., 2009; Savagner et al., 2005). In the chick embryo, Snai2 is expressed in cells
undergoing EMT and is crucial to primitive streak formation, endocardial cushions,
decondensing somites, and palate closure (Cobaleda et al., 2007). It is also highly
expressed in adult tissues such as the skin, stomach, kidney, lung, and uterus (Cohen et
al., 1998; Parent et al., 2004; Parent et al., 2010). Much of what is known about Snai2
was derived from loss-of-function mutations (Jiang et al., 1998; Sanchez-Martin et al.,
2003; Sanchez-Martin et al., 2002). Mice deficient in Snai2 are viable but have a white
forehead blaze, patchy depigmentation, macrocytic anemia, and are infertile (PerezLosada et al., 2002). These studies suggest that Snai2 may play an important role in
melanocyte stem cells, hematopoietic stem cells, and germ cells.

FIGURE 4.1. Transcription factor Snai2. Snai2 is a member of the Snail superfamily of
transcriptional repressors. It is 268 amino acids in length and contains five zinc fingers.

In addition, SNAI2 deletions have been implicated in two melanocyte
development disorders characterized by white-spotting – Waardenburg syndrome and
piebaldism. Waardenburg syndrome (WS) is a congenital disorder caused by defective

61

embryonic neural crest function, and there are four variants (WS1, WS2, WS3, and
WS4). WS1, WS3, and WS4 relate to failures of neural crest derivatives, and WS2 is a
failure in the melanocytes (Cobaleda et al., 2007; Sanchez-Martin et al., 2002). In some
patients with WS, homozygous deletions of SNAI2 have been the only detected
abnormality (Sanchez-Martin et al., 2002). In piebaldism, this disorder results from
mutations in the KIT proto-oncogene (Giebel and Spritz, 1991), which contains Snai2 as
a downstream target in the kit signaling pathway. Individuals with piebaldism have white
finger tips, long nails, and patchy hypopigmentation. In patients with piebaldism, though
there were observable differences in the SNAI2 gene, there was no detectable defect in
the KIT gene, implicating Snai2 as a cause for piebaldism (Sanchez-Martin et al., 2003).
Snai2 was also shown to be required for reepithelialization (Chandler et al., 2007;
Hudson et al., 2009; Savagner et al., 2005). As mentioned above, Snai2 is an important
downstream effector of the EGFR (Arnoux et al., 2008; Kusewitt et al., 2009).
Activation of the EGFR induces Snai2, and reepithelialization is compromised in Snai2
null mice (Kusewitt et al., 2009; Savagner et al., 2005). Furthermore, Snai2 null mice
display decreased epithelial outgrowth from ex vivo skin explants (Kusewitt et al., 2009),
and exposure of the null mice to ultraviolet radiation resulted in chronic, non-healing
wounds (Hudson et al., 2009). In contrast, wild type mice achieved complete wound
closure, further demonstrating the importance of Snai2 in reepithelialization.
While Snai2 is known to be required for successful reepithelialization, its role in
diabetes has not been elucidated. The literature on EGFR and diabetes and the lack of
literature involving Snai2 and diabetes emphasizes the need for further research on
reepithelialization in the diabetic environment. The goal of the following study was to
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investigate the role of transcription factor Snai2/Slug in reepithelialization, more
specifically, its involvement in impaired diabetic wound healing.
In the present study, we modeled a diabetic environment by exposing human
keratinocytes to the AGE precursor glyoxal, one of the best-studied reactive AGE
intermediates. We hypothesized that EGF-stimulated, as well as basal, Snai2 protein
decreases as a consequence of glyoxal exposure. In addition, glyoxal will impair
epithelial outgrowth of skin explants from mice. Lastly, transgenic mice over-expressing
Snai2 protein may be sufficient to overcome impairments in epithelial outgrowth as
assessed using explants. The results of this study may suggest that critical intracellular
proteins may be targets of glycation and contribute to impaired wound reepithelialization
in diabetes. In addition, we may then be able to implicate Snai2 in diabetes-impaired
wound healing and identify it as a potential therapeutic target for reepithelialization.

4.2 Materials and Methods
Squamous cell carcinoma cells (SCC 12F) cells and normal keratinocytes were
used in the following experiments. These keratinocytes were exposed to glyoxal and
stimulated with EGF. Assays used to assess cell signaling and function include the
following:
Section 2.1 – Cell culture
Section 2.1.1 – Cell culture drug treatments
Section 2.1.4 – Immunoblot analysis
Section 2.1.5 – qRT PCR
Section 2.1.6 – Immunoprecipitation
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Section 2.2 – Animal studies
Section 2.2.1 – Transgenic mice
Section 2.2.2 – Epithelial outgrowth
Section 2.2.3 – Immunocytochemistry
Section 2.2.5 – Epidermal protein isolation
Section 2.3 – Statistical analysis

4.3 Results
Glyoxal decreases Snai2 protein levels
In Chapter 3, we demonstrated the inhibitory effect of glyoxal on the
reepithelialization component of wound healing. Because the impact of glyoxal on cell
migration was more pronounced than that observed for proliferation, we tested the effects
of glyoxal on Snai2, a critical mediator of epithelial outgrowth downstream of EGFR
activation. The transcription factor Snai2 is an effector of EGF-stimulated
reepithelialization and is required for effective epithelial outgrowth (Hudson et al., 2009;
Savagner et al., 2005). When SCC 12F cells were treated with EGF, Snai2 protein
increased compared to non-treated cells (Figure 4.2A and 4.2B). However, glyoxal
significantly inhibited EGF-stimulated Snai2 protein expression (**p<0.01).
Interestingly, a time-dependent decrease of basal Snai2 protein was detected in response
to glyoxal (>8 h, *p<0.05) (Figure 4.2C and 4.2D). Similar results were observed in
normal human keratinocytes (Figure 4.2E and 4.2F).
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FIGURE 4.2. Glyoxal down-regulates EGF-stimulated and basal Snai2 protein. (A)&(B) SCC 12F
cells were treated with 0.5 mM glyoxal (GO) and 10 nM EGF for 24 h. Protein was analyzed for EGFstimulated Snai2 protein. (C)&(D) SCC 12F keratinocytes were exposed to 0.5 mM GO for 32 h. Basal
Snai2 protein levels were evaluated. (E)&(F) Normal keratinocytes were exposed to 0.5 mM GO over
24 h. Basal Snai2 was evaluated by immunoblotting. Densitometries were normalized to β-Tubulin and
to either “NT+EGF” (B) or to “NT” (D, F). Results are representative of at least three independent
experiments. Error bars are defined as mean +/- SEM. One-way ANOVA and Tukey’s post-test
revealed statistical significance *p<0.05, **p<0.01, and ***p<0.001.
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We then measured Snai2 protein levels in ex vivo skin explants. Tissues were
isolated from FVB mice and exposed to 0.5 mM glyoxal for 24 h. Immunocytochemistry
was performed to analyze changes in Snai2 protein between glyoxal-treated and untreated
tissues. In agreement with what was observed in the immunoblots (Figure 4.2), exposure
of glyoxal to explants resulted in decreased Snai2 protein (Figure 4.3).

FIGURE 4.3. Snai2 protein is decreased in tissue explants. Ex vivo skin explants were isolated from
mice and exposed to 0.5 mM glyoxal (GO) for 24 h. Snai2 was evaluated by immunocytochemistry
(A), and results are expressed as “Mean Intensity/Cell” (B). Results are representative of two animals
per group.
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A lower dose of glyoxal (0.2 mM) was also tested and assessed for effects on
Snai2 protein. This dose was chosen based on the observation that very low levels of
modified proteins are detected following exposure to keratinocytes for 24 h (Chapter 3,
Figure 3.6). There was no significant effect of the low dose glyoxal on Snai2 during the
24 h time period tested (Figure 4.4).

FIGURE 4.4. Low dose glyoxal does not decrease Snai2 protein. SCC 12F keratinocytes were
treated with 0.2 mM glyoxal for the indicated times. The immunoblot (A) and densitometry (B)
represent basal Snai2 protein levels. β-Tubulin was used as a loading control. Results are
representative of four independent experiments. Error bars are defined as mean +/- SEM. Oneway ANOVA and Tukey’s post-test did not show statistical significance.

In addition, while it was demonstrated that a closely related family member, Snai1
(Snail), was enhanced by the AGE precursor, methylglyoxal (Hirahara et al., 2009), we
observed no effect on Snai1 following exposures to glyoxal (Figure 4.5) suggesting
glyoxal may be specifically targeting certain proteins rather than acting ubiquitously.
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Furthermore, the decrease of Snai2 protein was not due to decreased mRNA expression
as measured by qRT-PCR (Figure 4.6).

FIGURE 4.5. Glyoxal has no effect
on Snai1 protein. (A) SCC 12F
keratinocytes were exposed to 0.5 mM
glyoxal (GO) for 24 h. Basal Snai1
protein levels were evaluated by
immunoblotting. (B) Densitometries
of immunoblots measuring Snai1
protein levels. Densitometries were
normalized to β-Tubulin and to “NT”
controls. Results are representative of
three independent experiments. Error
bars are defined as mean +/- SEM.
One-way ANOVA and Tukey’s posttest revealed no statistical effect.

FIGURE 4.6. Glyoxal does not affect
Snai2 at the transcriptional level. RNA
was isolated from SCC 12F keratinocytes
exposed to 0.5 mM glyoxal over a 24 h
period. One-way ANOVA and Tukey’s
post-test revealed statistical significance
(*p<0.05) at the 8 h treatment but no
overall inhibitory effect of glyoxal on Snai2
mRNA levels. Results are representative of
three independent experiments. Error bars
are defined as mean +/- SEM.
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Snai2 is covalently modified by glyoxal
Because we observed an increase in covalently modified proteins with increasing
glyoxal dose and exposure time (Chapter 3, Figure 3.6), we tested the hypothesis that
Snai2 is a target for glyoxal-induced glycation. To determine whether Snai2 was
modified, we immune-precipitated Snai2 from glyoxal-treated cells and found that Snai2
was modified by CML as detected by immunoblot analysis (Figure 4.7A). When the
keratinocytes were pre-treated with 5 mM aminoguanidine (AG), a potent glycation
inhibitor (Brownlee et al., 1986), and then exposed to glyoxal, Snai2 protein was
preserved (Figure 4.7B and 4.7C), further indicating that the decrease in protein level is
due to glycation and that Snai2 is a target for CML modification.

FIGURE 4.7. Glyoxal leads to covalently modified Snai2. (A) Keratinocytes were exposed to 0.5 mM
Glyoxal (GO) over 24 h. Snai2 was immunoprecipitated and immunoblotted for CML. (B)&(C) Cells
were pre-treated with 5 mM aminoguanidine (AG) and exposed to 24 h 0.5 mM GO. Protein was
immunoblotted for Snai2. Densitometries in (B) were normalized to β-Tubulin. Results are
representative of at least three independent experiments. Error bars are defined as mean +/- SEM. Oneway ANOVA and Tukey’s post-test demonstrate significance *p<0.05 and **p<0.01.
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Enhancing Snai2 protein promotes epithelial outgrowth in the presence of glyoxal
Because Snai2 was decreased and modified by glyoxal, we explored the
possibility of enhancing Snai2 to promote epithelial outgrowth. Protein from the
epidermis of wild type and Snai2 transgenic FVB mice was collected. The epidermal
layer was separated from the dermal layer, and protein from the epidermal layer was
extracted and analyzed via immunoblot. The transgenic mice displayed approximately
three-fold higher levels of Snai2 in the epidermis compared to wild type mice (Figure
4.8A and 4.8B). Skin explants isolated from both wild type and Snai2 over-expressing
mice were grown in culture over 5 d. The over-expressing mice showed a significant
increase in outgrowth compared to wild type mice after 5 d in culture (Figure 4.8C and
4.8D), demonstrating the ability of Snai2 to enhance epithelial outgrowth.
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FIGURE 4.8. Snai2 protein over-expression in mice promotes epithelial outgrowth. (A)&(B) Protein
was isolated from mouse epidermis. Differences in Snai2 between wildtype (WT) and Snai2 overexpressing (OE) mice measured by immunoblot. (C) Skin explants were isolated from mice and cultured
for 5 d. Epithelial outgrowth of keratinocytes was observed by taking phase contrast microscopy images.
Dashed line indicates migrating front. Scale bar equals 200 µm. (D) Outgrowth of epithelial cells was
evaluated by measuring the area around explants. Results are representative of five mice per group for
(A)&(B) and at least seven mice per group for (C)&(D). Error bars are defined as mean +/- SEM.
Student’s t-test for the immunoblots and two-way ANOVA with Bonferroni’s post-test for the explants
demonstrate significance *p<0.05.

Explants were then isolated from wild type and Snai2 over-expressing mice. The
tissues were exposed to 0.5 mM glyoxal over a 5 d period (Figure 4.9A). Image analysis
and outgrowth area measurements over the incubation period demonstrate improved
epithelial outgrowth in the over-expressing mice compared to wild type, and this was
significant as early as 3 d after the addition of glyoxal (Figure 4.9B). These data suggest
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the potential of Snai2 over-expression to promote epithelial outgrowth under diabetic
conditions.

FIGURE 4.9. Snai2 protein over-expression in mice promotes epithelial outgrowth in the
presence of glyoxal. (A) Skin explants isolated from the dorsal side of wild type (WT) and Snai2
over-expressing (OE) mice were cultured for 5 d. Explants were exposed to 0.5 mM glyoxal (GO), and
epithelial outgrowth of keratinocytes was observed by phase contrast microscopy. Dashed line
indicates migrating front. Scale bar equals 200 µm. (B) Outgrowth of epithelial cells was evaluated by
measuring the area around explants. Results are representative of at least seven mice per group. Error
bars are defined as mean +/- SEM. Two-way ANOVA with Bonferroni’s post-test demonstrates
significance *p<0.05 and ***p<0.001.

4.4 Discussion
Elevated AGEs are present in numerous pathologies including Alzheimer’s
disease, arthritis, and diabetes (Singh et al., 2001; Takeuchi and Yamagishi, 2008;
Vytasek et al., 2010) and are believed to impair protein function (Ahmed, 2005). An
increasing body of evidence suggests that glycation disrupts various aspects of the wound
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healing cascade (Ahmed, 2005; Huijberts et al., 2008; Peppa and Raptis, 2011).
Exposure of rats to the AGE precursor methylglyoxal decreased the numbers of cells
actively migrating into the wound, decreased angiogenesis, and reduced secretion and
accumulation of extracellular matrix components (Berlanga et al., 2005). In diabetic
db/db mice fed a high AGE diet, increased CML was present in wound tissue, and these
mice displayed a sustained inflammatory response and incomplete wound closure (Peppa
et al., 2003). Conversely, restricting dietary AGE in diabetic mice improved wound
repair compared to those fed a high AGE diet (Peppa et al., 2003). In addition, our
studies demonstrate the AGE precursor glyoxal decreases keratinocyte migration and
epithelial outgrowth from skin explants ex vivo. There is mounting evidence implicating
AGEs in defective cell locomotion and survival (Loughlin and Artlett, 2009; Morita et
al., 2005; Zhu et al., 2011), further connecting AGEs to impaired diabetic wound healing.
In the present study, Snai2 was identified as a novel target for down-regulation by
the AGE precursor glyoxal. Reduction of Snai2 protein is predicted to impair
reepithelialization based on its demonstrated role in keratinocyte migration and wound
repair (Chandler et al., 2007; Hudson et al., 2009; Savagner et al., 2005; Shirley et al.,
2010). Snai2 was up-regulated at the margins of healing wounds (Savagner et al., 2005),
and wound sections obtained from non-healing canine corneas were deficient in Snai2
(Chandler et al., 2007). Furthermore, epithelial outgrowth was impaired in both canine
corneas and Snai2 null mice skin explants (Chandler et al., 2007; Kusewitt et al., 2009;
Savagner et al., 2005), suggesting that Snai2 deficiency may be associated with failure to
heal. Because Snai2 has been shown to be an essential mediator of EGFR-mediated
keratinocyte outgrowth (Arnoux et al., 2008; Kusewitt et al., 2009), the impact of glyoxal
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and CML on both EGF-stimulated and basal Snai2 levels could contribute to deficits in
reepithelialization.
Determinants of lysine glycation include the number and the density of lysine
residues in a peptide, residue position, and availability of the residues on the protein
surface (Kueper et al., 2007; Venkatraman et al., 2001). Snai1 and Snai2 are highly
related proteins, but Snai1 was not down-regulated in response to glyoxal, demonstrating
selectivity in protein glycation. Interestingly, Snai2 and Snai1 differ in lysine content
(8.2% versus 5.3%, respectively), and Snai2 contains 3 lysine pairs compared to a single
pair in Snai1, another factor thought to contribute to the likelihood of glycation. The
immediate impact of glyoxal-induced modification of Snai2 is unclear. It is possible that
covalent modification of Snai2 may be promoting protein degradation (Bulteau et al.,
2001; Cervantes-Laurean et al., 2005) as our immunoblots demonstrated decreased levels
of Snai2 following glyoxal exposure. However, additional studies need to be done to
further explore the glyoxal-Snai2 relationship.
Furthermore, we demonstrated that Snai2 over-expression in skin could promote
epithelial outgrowth under diabetic conditions ex vivo. Though enhancing Snai2 may
increase reepithelialization, Snai2 modulation may also affect inflammation,
angiogenesis, the extracellular matrix, differentiation, and apoptosis (Shirley et al., 2010).
To the best of our knowledge, the effect of other reactive AGE intermediates, such as
methylglyoxal and 3-deoxyglucosone, on Snai2 has not been explored, so it is possible
that other AGE precursors may also have an effect on Snai2-dependent wound
reepithelialization. Together, the findings suggest a link between increased glycation that
occurs in diabetes and impaired wound closure through down-regulation of Snai2.
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Moreover, enhancing Snai2 is an attractive mode of promoting reepithelialization in
diabetes.
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CHAPTER 5
Future Directions and Perspectives
Diabetes mellitus is a debilitating metabolic disease that can ultimately result in
death (Galtier, 2010; Setacci et al., 2009). One troubling complication is non-healing
skin wounds, and we investigated the effect of the advanced glycation end product
precursor, glyoxal, on proteins known to be required for successful reepithelialization
(Usui et al., 2008; Velander et al., 2008). The data presented in this dissertation presents
for the first time a role of transcription factor Snai2 in diabetes-impaired wound
reepithelialization.

5.1 AGEs as culprits in diabetes-impaired wound repair
An important consequence of diabetes is the elevation of advanced glycation end
products (AGE), which are present in numerous pathologies and have been implicated in
impaired diabetic wound healing (Ahmed, 2005; Huijberts et al., 2008; Peppa and Raptis,
2011; Singh et al., 2001; Takeuchi and Yamagishi, 2008; Vytasek et al., 2010). There is
mounting evidence implicating AGEs in defective cell locomotion and survival (Loughlin
and Artlett, 2009; Morita et al., 2005; Zhu et al., 2011), and our studies further
demonstrate keratinocyte migration and epithelial outgrowth impairments as a
consequence of glyoxal exposures (Chapter 3). In addition, exposing glyoxal led to
increased levels of covalently modified proteins and demonstrates the broad range of
potential glycation targets (Chapter 3). A limitation of the studies discussed in this
dissertation is that the highest dose of glyoxal tested (0.5 mM) is greater than what is
found in diabetic patients (Lapolla et al., 2003), but the concentrations and times of
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exposure are comparable to what has been used in other studies (Berge et al., 2007; Nass
et al., 2010; Rattan et al., 2007; Sliman et al., 2010). In addition, AGE formation and
accumulation may take years to occur. Therefore, for the purposes of scientific studies,
the dose is increased, and the exposure times are decreased to mimic a diabetic
environment. More studies will be needed in order to ascertain which proteins are targets
of glycation and whether or not they play important roles in the healing process.
Identifying the specific proteins being AGE-modified may allow us to target these
proteins to promote healing over the observed deficiencies in diabetic wound healing.

5.1.1 Selectivity in protein glycation
There is evidence for selectivity of protein glycation; sites of glycation include
thiols, lysine, and arginine residues, and the N-terminus of proteins (Miller et al., 2003;
Mostafa et al., 2007; Schwarzenbolz et al., 2008; Venkatraman et al., 2001). Other
factors that influence glycation are protein turnover, intracellular localization, and
structure (Kueper et al., 2007). The traditional belief is that collagen and other
extracellular matrix components and proteins such as myelin, plasminogen activator 1,
and fibrinogen, are recognized targets of glycation because they are long-lived and easily
accessible to AGE modification (Goh and Cooper, 2008; Kragstrup et al., 2011; Zieman
and Kass, 2004). However, there is evidence for modification of intracellular proteins as
well (Kueper et al., 2007). Lysine glycation is dependent on the number and density of
lysine residues in a peptide, residue position, and availability of the residues on the
protein surface (Kueper et al., 2007; Venkatraman et al., 2001). Though Snai2 was
shown to be modified by CML following glyoxal exposure, the closely related family
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member Snai1 was not, suggesting selectivity in glycation. In addition to Snai1, we also
examined the effect of glyoxal on other intracellular proteins such as Specificity Protein 1
(SP1), poly (ADP-ribose) polymerase (PARP) (Figure 5.1), β-Tubulin, glyceraldehyde 3phosphate dehydrogenase (GAPDH), and EGFR (Chapter 3, Figure 3.7). We found that
out of all proteins tested, Snai2 was the only protein affected. Evidence of CMLmodification of Snai2 supports the conclusion that Snai2 is a target of glycation.
Furthermore, we demonstrated the ability of Snai2 protein over-expression to overcome
the inhibition of epithelial outgrowth caused by glyoxal.

FIGURE 5.1. Glyoxal has no effect on Sp1 and PARP protein. SCC 12F keratinocytes were treated
with 0.5 mM glyoxal for the indicated times. (A)&(B) Protein was analyzed for changes in transcription
factor Sp1. (C)&(D) Protein was analyzed for changes in PARP. β-Tubulin was used as a loading
control. Results are representative of one independent experiment for Sp1detection and three
independent experiments for PARP assessment. Error bars are defined as mean +/- SEM. One-way
ANOVA and Tukey’s post-test did not show statistical significance.
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This work provides more evidence of an emerging idea that glycation occurs not
just to proteins with long half-lives such as with collagen and other easily available
extracellular matrix proteins. It demonstrates that glycation may be a specific event and
can even affect nuclear proteins. Therefore, it is crucial to begin identifying which
proteins are targets of glycation to rectify impairments in cell function.

5.2 Current therapies in diabetic ulcer treatment
Diabetic foot complications are the most common cause of non-traumatic lower
extremity amputations in the world (Wu and Armstrong, 2005). Diabetic wound care
begins by assessing the state of the wound and asking questions such as what is the
etiology and the diagnosis of the wound? Why has the wound become chronic? Why has
the healing rate slowed or stopped? Many factors contribute to the state of a chronic
diabetic wound (Figure 5.2), making successful healing difficult.

FIGURE 5.2. Factors that contribute to a chronic wound state in diabetes. Many different
factors play roles in wound healing, making repair a complicated process.
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The International Working Group of the Diabetic Foot has issued guidelines on
the management of the diabetic foot since 1999, but even today, effective treatment
remains a major problem (Game et al., 2012). Diabetic wound treatments range
anywhere from improving patient nutrition to full limb amputations.

5.2.1 Pharmacological treatment of diabetic ulcers
Wound care also includes maintenance of a moist environment through hydrogels,
hydrocolloids, foams, and alginates (Janis et al., 2010). These products may contain
silver to provide anti-microbial activity (Janis et al., 2010). As measured by the
migration of new epithelium into the wound bed, moist wounds healed two to three times
faster than dry wounds, demonstrating the importance of keeping wounds wet (Winter,
1962). In contrast, a dry environment impairs fibroblast proliferation and prevents cell
migration (Chang et al., 1996). A moist environment also promotes granulation tissue
formation and epithelial cell migration, accelerates angiogenesis, increases the
breakdown of necrotic tissues and fibrin, and potentiates interactions between growth
factors and target cells.

5.2.2 Skin substitutes promote wound healing
The use of bioengineered skin has also been explored to heal wounds that have
not closed by at least 50% after four weeks. For example, Dermagrafts and Apligrafts act
as scaffolds and skin substitutes. Dermagrafts are produced by culturing human dermal
fibroblasts from newborn foreskin onto a mesh scaffold. As the fibroblasts proliferate,
they secrete collagen, matrix proteins, growth factors, and cytokines to help promote
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reepithelialization. It was shown that patients using the fibroblast-derived dermis healed
faster and had lower rates of infection than those who did not use the dermagraft (Hanft
and Surprenant, 2002; Marston et al., 2003). An alternative substitute, the Apligraft, is
bi-layered and contains an epidermis and a dermis cultured from neonatal foreskin. The
Apligrafts produce all cytokines and growth factors expressed in normal healing skin.
Apligrafts have been shown to heal chronic ulcers faster than conventional debridement
and saline dressing therapy (Veves et al., 2001). Therefore, the use of skin substitutes
does provide further assistance in promoting wound repair. However, these treatments
are costly.

5.2.3 Tissue debridement and amputation
If necessary, necrotic and devitalized tissues are removed by debridement, which
converts a chronic wound into an acute wound and removes all the damaged or dead
tissues that harbored harmful bacteria. Decisions to amputate are performed only if
absolutely necessary and begin with removal of small tissues, such as the toes. However,
this can escalate into full removal of the limb. If an amputation is needed, wounds are
sutured closed, and wound vacs are used to promote the granulation process of healing
(Janis et al., 2010; Nather, 2011).
Though many factors play roles in successful diabetic wound closure, treatment
can also be expensive or ineffective. Much is left to be discovered regarding specific
factors that prevent diabetic tissue repair. The work in this dissertation has identified a
novel protein known to be crucial for successful reepithelialization that is decreased in a
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diabetic state. Thus, further examination of the effect of diabetes on Snai2 protein must
be explored.

5.3 Exploring pharmacological therapies to enhance reepithelialization
It is clear that the current methods used to treat chronic wounds are ineffective in
stopping infection, in promoting wound closure, and in preventing amputations.
Therefore, there is a continued need to explore alternative therapies.

5.3.1 Targeting EGFR to promote healing
As discussed in Chapter 3, many studies have demonstrated the crucial
contribution of the epidermal growth factor receptor (EGFR) in wound healing.
Furthermore, there is evidence of EGFR involvement in diabetic tissue repair. Currently,
investigations into using recombinant EGF to promote tissue repair in diabetic rats
(Dogan et al., 2009; Lao et al., 2012) and prevent amputation of diabetic foot ulcers are
being conducted (Tiaka et al., 2012). EGF treatment alone has demonstrated successful
wound closure in a significant number of diabetic patients (Fernandez-Montequin et al.,
2007; Fernandez-Montequin et al., 2009; Tuyet et al., 2009). When given in combination
with other therapies, EGF treatments resulted in even greater healing compared to EGF
alone (Hong et al., 2006; Tsang et al., 2003). More importantly, reduced amputations
were observed with EGF applications (Acosta et al., 2006; Tsang et al., 2003).
Optimizations on concentrations and method of administration, such as through
dressings, intra-lesional injections, and EGF-conjugated nanofibers (Berlanga-Acosta,
2011; Choi et al., 2008; Fernandez-Montequin et al., 2009; Lao et al., 2012), are yet to be
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determined but offer attractive possibilities into promoting tissue repair. However,
though these studies and treatments show potential in improving reepithelialization, they
may still be met with limited success. It has been demonstrated that the EGFR itself is a
target of glycation (Portero-Otin et al., 2002), yet we found no glycation of the EGF
ligand, suggesting AGEs target the receptor. It is possible the covalent modification can
be occurring in the cysteine-rich regions of the binding site required for proper receptor
activation (Garrett et al., 2002; Ward et al., 2007). Because the EGFR may be modified
in some diabetic wound cases, it is important to continue exploring other protein targets
to promote healing.

5.3.2 Snai2/Slug is a novel therapeutic target in diabetic wound healing
The data presented in this dissertation demonstrate impairments in EGFR
activation and its function following glyoxal exposure. However, enhancing Snai2
protein by bypassing the EGFR may be sufficient to overcome the reepithelialization
impairments observed in diabetes (Figure 5.3). In data recently obtained from our
collaborator Dr. Donna F. Kusewitt (University of Texas MD Anderson Cancer Center,
Smithville, Texas), wounded diabetic mice sustained a larger wound bed length
compared to wounded control mice. In addition, basal Snai2 protein was detected at
lower levels in wounded diabetic mice compared to controls. Therefore, further
exploration of the potential of enhancing Snai2 levels to overcome impaired
reepithelialization is of interest.
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FIGURE 5.3. Enhancing Snai2 protein to
promote reepithelialization. The EGFR
signaling and function are impaired. Therefore,
exploration of alternative methods, such as with
tetracycline and TGF-β, to bypass the EGFR and
induce Snai2 protein to overcome
reepithelialization defects is of interest.

In addition to the EGFR signaling pathway to induce Snai2, tetracyclines are
known to enhance expression of TGF-β, a growth factor important in both corneal wound
healing and Snai2 induction (Aomatsu et al., 2011; Chandler et al., 2007; Shlopov et al.,
2001). Crosstalk between the EGFR-ERK and TGF-β-SMAD signaling pathways is
known to enhance TGF-β-dependent responses (Aomatsu et al., 2011; Hayashida et al.,
2003; Uttamsingh et al., 2008). It was recently shown in dogs with refractory corneal
ulcers that topical tetracycline ophthalmic ointment resulted in a significantly shorter
healing time than dogs who received a control treatment (Chandler et al., 2010). In future
studies, we can then move to in vivo studies involving diabetic mice. These mice will be
wounded, and we can test the ability of a topical tetracycline ointment to enhance wound
healing.
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We first examined the ability of tetracycline hydrochloride to induce Snai2
protein in SCC 12F keratinocytes as described in Section 2.1.1. The preliminary data
shows that with increasing exposure to tetracycline hydrochloride, enhanced levels of
Snai2 protein are observed (Figure 5.4A and 5.4B). This suggests that it may be possible
to induce Snai2 protein in an EGF-independent mechanism, and therefore it may be
considered in promoting healing in diabetes.

FIGURE 5.4. Tetracycline hydrochloride and TGF-β induce Snai2 protein in keratinocytes. SCC
12F cells were exposed to 10 µM tetracycline hydrochloride (Tet) (A)&(B) or to 10 ng/ml TGF-β
(C)&(D) for 96 h. Snai2 protein levels were evaluated via immunoblot, and densitometries revealed
increased Snai2 following Tet and TGF-β exposures. Results are representative of two experiments
for (A)&(B) and one experiment for (C)&(D). Error bars are defined as mean +/- SEM.

Tetracycline is a drug of choice to use in these studies because it is already
commercially available in various forms, and it induces Snai2 by up-regulating TGF-β
(Chandler et al., 2007). However tetracycline hydrochloride has a short-acting half-life
of 6-8 hrs. Therefore, we may need to use a different form of tetracycline, such as
doxycycline, which has been used in other studies (Chandler et al., 2007) and has a long85

acting half-life of 18-22 hrs. In addition, if the observed increases in Snai2 are too mild
for the short duration of our experiments (~1 wk), direct treatment with TGF-β may be an
alternative approach to enhance Snai2 (Figure 5.4C and 5.4D). In initial studies, we
exposed tissue explants obtained from mice (Section 2.2.2) to 10 ng/ml TGF-β and to 0.5
mM glyoxal. We observed that TGF-β induced explant outgrowth (Figure 5.5). In
contrast, glyoxal impaired epithelial outgrowth, which was similar to what was observed
in Chapter 3, Figure 3.4. However, the combination of TGF-β and glyoxal was sufficient
to induce keratinocyte outgrowth. This further demonstrates that though Snai2 protein is
impaired under diabetic conditions, it is possible to boost Snai2 levels with
pharmacological inducers. Therefore, we may have a novel alternative method to
promote wound healing in diabetes.

FIGURE 5.5. TGF-β induces epithelial outgrowth in the presence of glyoxal. (A) Skin explants
isolated from the dorsal side of wild type were cultured for 3 d with 10 ng/ml TGF-β and 0.5 mM
glyoxal (GO). Epithelial outgrowth of keratinocytes was observed by phase contrast microscopy.
Dashed line indicates migrating front. (B) Outgrowth of epithelial cells was evaluated by measuring
the area around explants. Results are representative of three mice per group. Error bars are defined as
mean +/- SEM.
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5.4 Future directions
The work discussed in this dissertation demonstrates signaling pathways known to
be required for successful wound closure are defective in a diabetic environment. In
addition, glycation is targeting Snai2 protein, a transcription factor required for
reepithelialization. However, Snai2 enhancement via a different signaling pathway,
TGF-β, is sufficient to promote cell migration. Thus, further studies are needed to
determine if targeting Snai2 in vivo can enhance wound healing.
It will be informative to investigate repair of full thickness wounds in the backs of
diabetic mice (Figure 5.6). Wounds will be created using 6 mm biopsy punches, and
healing and rates of closure will be evaluated between wild type and diabetic mice.
Parameters measured from a wound include the wound margin length (the distance the
cells have migrated into the wound) and the wound bed length (the diameter of the
wound not yet healed). In addition, the wounds can be isolated from the mice and
analyzed using immunohistochemistry. Snai2 protein can be analyzed using
immunofluorescence to determine if there is a correlation between wound healing rate
and Snai2 protein levels, location, and modification.

FIGURE 5.6. Live animal wounding studies. Full thickness wounds will be introduced into the
backs of mice. Rates of wound closure as well as wound bed and margin lengths can be examined
comparing wild type and diabetic mice. Wounds can also be harvested from mice and analyzed for
changes in Snai2 protein using immunohistochemistry.
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Following exploration of protein differences between wild type and diabetic mice,
we will wound diabetic mice and treat the damaged tissue with tetracycline. As
discussed above, tetracycline has been demonstrated to induce Snai2 protein and promote
wound healing in canine corneas (Chandler et al., 2007; Chandler et al., 2010). By
treating diabetic wounds with tetracycline, we hope to observe significant improvements
in closure compared to untreated diabetic wounds. This data will contribute to
possibilities of cheaper, more manageable, wound care. In addition, it will be a more
targeted approach, as current therapies aim to promote an environment suitable for
overall healing and do not address the underlying causes of diabetic repair deficiencies.

5.4.1 Applications of animal models in diabetes research
Our future studies will include the use of diabetic animals. Most often, rodents
are used due to their size, cost, and the ability to provide a controllable diabetic
environment in vivo. The models can be divided into two categories – geneticallyinduced spontaneous diabetes models and chemically-induced non-spontaneous diabetes
models (Islam and Loots du, 2009). Three examples of popular animal models of
diabetes include the ob/ob, the db/db, and the Streptozotocin (STZ) mice, where the
ob/ob and the db/db mice are genetically-induced models of diabetes, and the STZ mouse
is a chemically-induced model.

5.4.2 Genetically-induced models of diabetes
The genetically-induced models develop diabetes spontaneously, may have
insulin resistance, and reduced β-cell mass (Kim et al., 1998). However, though the
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genetic animal models have advantages, they are difficult to maintain, are expensive, and
do not fully express the pathology of diabetes (Peters and Schmitt, 2012).
The ob/ob mouse is a model of type 2 diabetes and obesity and was created by
Jackson Laboratories in Bar Harbor, Maine (Ingalls et al., 1950) (Lindstrom, 2007). The
affected gene is a recessive mutation in the obese (ob) gene (Zhang et al., 1994), resulting
in an inability to produce the hormone leptin. This hormone is produced primarily in
adipose tissue, and its major role is to regulate appetite by signaling to the brain that one
has had enough to eat (Feve and Bastard, 2012). Because ob/ob mice lack this hormone,
their food intake is uncontrolled and result in obesity. At birth, the mutant mice look
similar compared to their littermates, but they gain weight quickly, reaching weights
three times that of unaffected mice. In addition to extreme obesity, the mice develop
hyperglycemia, increased insulin production (Garthwaite et al., 1980; Mayer and
Barrnett, 1953), and suffer from infertility. Interestingly, the ob/ob syndrome can be
reversed by exogenous leptin or transfection with the leptin gene (Halaas et al., 1995;
Larcher et al., 2001; Pelleymounter et al., 1995). Because they have large pancreatic
islets and a higher number of insulin-producing β-cells, they are often used in studies of
β-cell function (Lindstrom, 2007) and have greatly advanced our understanding of
diabetes, obesity, and metabolism. Furthermore, this model has been demonstrated to
suffer impaired wound healing with defective immune functions, decreased collagen
deposition, and reduced reepithelialization (Frank et al., 2000; Goodson and Hunt, 1986;
Goren et al., 2003; Kampfer et al., 2005; Stallmeyer et al., 2001a; Stallmeyer et al.,
2001b) making it a useful model for diabetic wound repair.
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Whereas ob/ob animals lack the hormone leptin, db/db animals lack functioning
receptors for leptin due to a homozygous point mutation in the gene encoding the
receptor. The leptin receptor is highly expressed in the hypothalamus, and animals with a
defect in the receptor are unable to regulate their energy stores. These animals become
obese by 3-4 weeks of age. The mice are insulin resistant, hypertriglyceridemic (high
blood levels of triglycerides, the most abundant fatty molecule), and have impaired
glucose tolerance (Lindstrom, 2007). This model is a popular animal model that has been
used to demonstrate wound healing defects. These mice display lower levels of growth
factors and receptors that result in a reduced wound healing rate (Tsuboi et al., 1992;
Werner et al., 1994), decreased epidermal nerves, and an inability to heal standard skin
wounds (Olerud, 2008). Lastly, slow wound healing in these mice may be due mainly to
impaired wound contraction (Chan et al., 2006; Sullivan et al., 2004), a major method of
wound closure in mice, adding to the benefits of this model.

5.4.3 Chemically-induced models of diabetes
In contrast to genetic models of obesity, chemically-induced diabetes can be
performed using mice that are normally not diabetic. They are cheaper to use than
genetically-modified models, and diabetes can be induced as simply as by high-fat diets
or by chemical injection (Rakieten et al., 1963). They also develop most of the
pathological symptoms associated with diabetes, making the chemical induction of
diabetes a popular method to use in research. However, no single model exists that
manifests all aspects of diabetes, which include neural, retinal, renal, and cardiac
complications.
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The Streptozotocin (STZ)-induced model is a chemically-induced model derived
from STZ, which is produced by Streptomyces achromogenes (Rakieten et al., 1963).
STZ-induced diabetes functions by destroying pancreatic β-cells through oxidative stress,
leading to insulin deficiency, hyperglycemia, and ketosis (Ozawa et al., 2011; Rerup,
1970; Yamamoto et al., 1981). Depending on the dose of STZ used, this model can
mimic both type 1 and type 2 diabetes (Rakieten et al., 1963). It is cytotoxic to
pancreatic β-cells after being transported through glucose transporter 2 (GLUT2),
allowing generation of a type 1 diabetes model (Schnedl et al., 1994). However, STZ
does not provide a state of insulin resistance, and can be given in combination with a
high-fat diet to create a model of insulin resistance, making a model of type 2 diabetes.
Blood glucose levels can reach over 250 mg/dL just days after the first STZ injection
(Graham et al., 2011; Kurihara et al., 2008).
This method is simple, cost effective, and can be used over a broad range of
animals. These mice display decreased granulation tissue accumulation (Cianfarani et al.,
2006; Goodson and Hung, 1977; Seifter et al., 1981), altered T-cell function, and
decreased macrophage phagocytosis (Seifter et al., 1981), characteristic of the diabetic
condition. However, induction of diabetes may take weeks, and there is high variability
in blood glucose levels (Rerup, 1970),
The exploration of diabetes and a better understanding of its causes and effects
are ongoing, and the use of animal models allows researchers to mimic diabetic
environments. Depending on what knowledge is desired, some models are more
appropriate than others, and the availability of various options will hopefully assist in
efficient and accurate studies of diabetes. With the availability of diabetic animals for
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research, we can investigate the use of pharmacological inducers of Snai2 to promote
wound healing.

5.5 Significance
In conclusion, the data presented throughout this dissertation advances the current
knowledge regarding the contributions of Snai2 in wound healing. More importantly, it
implicates Snai2 as having a crucial role in diabetes-impaired wound repair in that this
protein known to be required for successful reepithelialization is covalently modified in
the diabetic environment. Thus, these studies identify Snai2 as an attractive therapeutic
target to promote wound closure in diabetes.
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